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Abstract. Positron emission tomography (PET) is now 
primarily used in oncological indication owing to the 
successful application of fluorine-18 fluorodeoxyglucose 
(FDG) in an increasing number of clinical indications at 
different stages of diagnosis, and for staging and follow- 
up. This review first considers the biological characteris- 
tics of FDG and then discusses methodological consider- 
ations regarding its use. Clinical indications are consid- 
ered, and the results achieved in respect of various or- 
gans and tumour types are reviewed in depth. The review 
concludes with a brief consideration of the ways in 
which clinical PET might be improved. 
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Introduction 
Positron emission tomography (PET) is an imaging tech- 
nology that delivers high-resolution images using bio- 
logically active compounds, ubstrates, ligands or drugs 
labelled with positron emitters [1]. These radiolabelled 
agents are primarily administered intravenously, distrib- 
uted according to blood flow and utilized or processed in
a manner virtually identical to their non-radioactive 
counterparts. They produce images and quantitative in- 
dexes of blood flow, glucose metabolism, amino acid 
transport, protein metabolism, neuroreceptor status, oxy- 
gen consumption or even cell division, etc. Since only 
tracer level amounts of material are administered, no 
pharmacological effect occurs and there is no perturba- 
tion of the targeted biochemical process [2-4]. Diagnos- 
ticians have traditionally been trained to analyse infor- 
mation provided by structural or anatomically based 
techniques. Biochemical processes are, however, altered 
in virtually all disease states and these alterations usual- 
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ly precede gross anatomical changes. With the advent of 
molecular biology-based medicine, a transition must be 
made to incorporate information based on biochemical 
perturbations into diagnostic information, without wait- 
ing for structural changes. PET is one of the few clinical 
imaging techniques that provides uch information. PET 
is also a very useful adjunct o anatomical imaging tech- 
niques, providing unique information and an additional 
dimension to the characterization f disease [5]. 
While applications initially focussed on the brain and 
the heart, PET is now primarily used in oncological indi- 
cations. This development has resulted from the success- 
ful application of fluorine-18 fluorodeoxyglucose (FDG) 
to a growing number of clinical indications at varying 
stages of diagnosis, staging and therapy follow-up of pa- 
tients with cancer of many types and origins [6-8]. 
FDG uptake in cancer tissue is well documented in
the literature and is based upon the increased glycolysis 
that is associated with malignancy as compared with 
most normal tissues [9, 10]. The availability of a radio- 
active glucose analogue and of PET has allowed the 
study of glucose uptake in vivo. Initial work focussed on 
primary brain tumours as brain PET scanners were most 
commonly available. Di Chiro [11] first demonstrated 
that FDG PET was able to discriminate brain tumour e- 
currences from post-therapy changes. PET also provides 
a method to assess tumour grade and to evaluate pa- 
tients' prognosis. With the advance of the whole-body 
imaging unit, the FDG technique has blossomed. 
It is therefore appropriate to review the advantages 
and limitations of FDG as a tumour-seeking a ent, its 
present and potential clinical role, the requirement for 
clinical improvement and widespread application of 
PET, and certain research perspectives. 
Biological characteristics of 18-FDG 
Use of FDG for in vivo cancer imaging is based on the 
observation of enhanced glycolysis in tumour cells. A 
high rate of "aerobic glycolysis" (degradation f glucose 
to lactic acid in the presence of oxygen) in several types 
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of cancer cells was first described by Warburg [12, 13]. 
This phenomenon has been linked to both an increase in 
the amount of glucose membrane transporters [14] and 
an increase in the activity of the principal enzymes con- 
trolling the glycolytic pathways. 
Uptake of glucose and FDG into malignant cells is fa- 
cilitated by an increased expression of the glucose trans- 
porter molecules at the tumour cell surface. Five trans- 
porters (GLUT1-GLUT5) are currently known and dis- 
tributed in variable quantities among different issues. 
GLUT1 and GLUT3 are the most frequent. GLUT4 de- 
pends on insulin for activation. Several papers suggest 
that activation of the gene coding for synthesis of the 
glucose transporter GLUT1 is a major early marker of 
cellular malignant transformation [15-20]. 
GLUT1 messenger RNA indeed increases 3-4 days 
before morphological transformation a d this increase is 
not correlated with the cell proliferation rate [21-23]. 
Transfection to rat fibroblast of activated ras  or s rc  on- 
cogenes results in an elevation of the cytosolic oncen- 
tration of mRNA responsible for the synthesis of glucose 
transporter [24]. In addition, an increased concentration 
of the mRNA has been linked to the increase in the num- 
ber of glucose transporters in the malignant cell. In man, 
overexpression of GLUT1 and GLUT3 has been ob- 
served in several tumour types, including cerebral tu- 
mours, hepatocellular carcinoma nd pancreatic tumours 
[25-28]. Furthermore, an increase in the activity of sev- 
eral enzymes controlling the glycolytic pathway has 
been demonstrated (hexokinase, phosphofructokinase, 
pyruvate dehydrogenase) [29]. For instance, several iso- 
enzymes of hexokinase have been observed in the No- 
vikoff ascites tumour [30]. 
FDG following intracellular t ansport is a substrate 
for hexokinase, the first enzyme of glycolysis. It is phos- 
phorylated to FDG-6-phosphate. However, the second 
enzyme, glucose-6-phosphate isomerase, which trans- 
forms glucose-6-phosphate into fructose-6-phosphate, 
does not react with FDG-6-phosphate. Further, as the 
concentration f glucose-6-phosphatase is v ry low (ex- 
cept in the hepatocyte), the reverse transformation is not 
possible and FDG-6-phosphate r mains trapped. Acces- 
sory metabolic pathways to gluconate and glucuronate 
are very slow and can be considered negligible within 
the time frame of the t8F half-life. The cellular concen- 
tration in 18F is therefore closely representative of the 
accumulated FDG-6-phosphate and of the glycolytic ac- 
tivity of exogenous glucose [31, 32]. 
Numerous tudies have attempted to relate cellular 
FDG uptake to the biological properties of the tumour 
such as the histological grade, the proliferative activity, 
the doubling time and the number of viable turnout cells. 
A positive correlation between FDG uptake and the tu- 
mour grade has been reported in several tumour types in- 
cluding cerebral gliomas [33], liver tumours [34], non- 
Hodgkin's lymphomas [35, 36] and some musculoskele- 
tal tumour types [37, 38]. The relationship between tu- 
mour grade and uptake is, however, less marked in pul- 
monary tumours [7]. In hepatocellular carcinoma, the 
growth rate and the activity of glycolytic enzymes are 
related [39]. In head and neck turnouts, the proliferative 
activity studied by DNA flow cytometry is related to 
FDG uptake while FDG does not reflect the turnout 
type. Further different cells of similar proliferative activ- 
ity appear to belong to two different groups based on 
FDG uptake, suggesting the influence of other factors 
[40]. In cultured human ovarian adenocarcinoma cells, 
FDG uptake is not related to proliferative activity but to 
the number of viable tumour cells [41]. In subcutaneous- 
ly transplanted tumour cells, Kubota et al. [42] analysed 
the intratumoral distribution of FDG and tritiated eoxy- 
glucose. Both tracers had a similar distribution pattern 
within the tumour with both autoradiographic methods. 
A maximum of 29% of glucose utilization was derived 
from non-tumorai tissue. It was concentrated in granulo- 
matous tissue and macrophages infiltrating the areas ur- 
rounding necrotic tumoral tissue. High accumulation of
FDG in the tumour is believed to represent high meta- 
bolic activity of the viable tumour cells [43, 44]. 
It is important to stress that FDG uptake by neoplastic 
turnouts in vivo remains under the dependence of other 
physiological factors, such as tissue oxygenation, re- 
gional blood flow and peritumoral inflammatory reac- 
tions [45-48]. FDG PET therefore must be considered as 
a very sensitive technique, but a technique whose speci- 
ficity is imperfect and must be compensated for by care- 
ful selection of patients and rigorous correlation with an- 
atomical images (including image fusion, whenever pos- 
sible) [49]. 
Other tracers designed to evaluate amino acid uptake 
(carbon-ll methionine) [44, 50-52], protein synthesis 
(1JC-tyrosine) [53] or DNA synthesis and cellular prolif- 
eration (llC-thymidine and 18F-fluorodeoxyuridine) [46, 
54] have been proposed as tumour imaging agents. How- 
ever, less experience has been accumulated using these 
tracers. While theoretically attractive, they are more dif- 
ficult to produce and usually do not provide the same 
image contrast that makes FDG so impressive (with the 
notable xception of J lC-methionine for brain turnouts). 
Use of tracer modelling technique is required and in par- 
ticular, labelled metabolites in blood and tissues have to 
be taken into account. For instance, no adequate model 
is yet available for HC-thymidine while it is now recog- 
nized that a significant part of the signal in tissues is re- 
lated to accumulation f 11CO2 ! [55]. 
Kubota et al. [50, 51] have compared the tumoral up- 
take of methionine (using 14C-methionine in place of 
11C-methionine) and FDG using the same tumour mod- 
els or experimental conditions for both tracers. 14C-Me- 
thionine uptake within viable tumour cells is relatively 
more important than the uptake of FDG. Indeed, FDG is 
taken up not only by viable tumour cells but also by the 
peritumoral granulation tissue, by activated macrophages 
within the turnout and by cells at the periphery of ne- 
crotic tumoral tissue. These observations suggest hat 
l~C-methionine could give false-negative r sults when 
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studying tumours with few active tumoral cells but mas- 
sive macrophage infiltration. On the other hand, during 
follow-up of therapy, and especially of radiotherapy, in 
the presence of numerous activated macrophages and 
prenecrotic tumoral~ cells, FDG could remain increased 
in the absence of proliferating tumoral cells. The choice 
between these two tracers therefore depends on the type 
of tumour studied and on the aim of the test. In general, 
to differentiate between benign and malignant tissues, 
FDG should provide more sensitive results than l lC-me- 
thionine [31, 50, 51]. 
A similar comparison has been performed by Minn et 
al. [44] using different models derived from three cellu- 
lar lines from head and neck epidermoid epithelioma. In- 
deed, the proliferation kinetics of head and neck tumours 
has important implications concerning the irradiation 
schemes. The uptake of FDG and of 14C-methionine ap- 
pears in that study to be well correlated to the pool of vi- 
able cells. Absolute methionine uptake, however, is 
smaller than that of FDG, especially during the exponen- 
tial and plateau proliferation phases, leading to relative 
underestimation of the number of tumoral cells when us- 
ing methionine. These two studies confirm the potential 
advantage of FDG for the study of the pool of viable 
cells. Methionine, on the other hand, appears uperior 
for evaluation of the number of proliferative cells. I IC- 
methionine could prove more favourable for evaluation 
of therapeutic efficacy, especially after adiotherapy. 
Other investigators have pointed out, however, that 
methionine, although a tracer of amino acid uptake, is 
not a tracer of protein synthesis, and they propose the 
use of ~lC-tyrosine instead, l~C-tyrosine would indeed 
be better suited to kinetic modelling of protein synthesis, 
but experimental nd clinical uses of this tracer are only 
beginning [56]. 
Methodological considerations 
The field of view of the PET camera is usually quite lim- 
ited as these instruments were initially developed for the 
heart and the brain, and because of cost constraints. It
varies between 10 and 16 cm in most scanners, with the 
largest field of view for a single acquisition being in the 
order of 25 cm. Most scanners consist of BGO or NaI 
crystals and the number of slices depends on the physi- 
cal size of the sampling elements and/or on the size of 
the digital matrix [57-59]. Resolution typically varies 
between 4 and 6 mm FWHM depending on the perfor- 
mance of the unit. An important consideration is the 
achievement of isotropic resolution and avoidance of 
off-centre degradation, ecessary for successful image 
reorientation. Effective clinical resolution can be further 
degraded by count statistics and the use of smoothing fil- 
ters. It is more typically around 6-10 mm depending on 
the instrument used. The use of single-photon emission 
tomographic (SPET) cameras with high-energy collima- 
tors remains unproven in oncology [60] while the use of 
dual-head large field of view cameras with coincidence 
correction ow appears feasible [61]. 
Instrument sensitivity is more important than count 
rate for whole-body PET and oncology as it allows opti- 
mal use of frequently limited tracer amounts, and direct- 
ly influences canning time. The advent of 3D-imaging 
capability has markedly increased the sensitivity of cur- 
rent scanners and allowed an increase in the signal to 
noise ratio while reducing the amount of tracers needed. 
Whole-body imaging is performed by successively 
displacing the patient bed over 1/2 to 1 time the field of 
view [62]. Some degree of overlap is preferable, espe- 
cially in the 3D-mode, to even out z-axis sensitivity 
changes due to varying effective axial incidence angle 
over the field of view and to avoid zip artefacts caused 
by patient motion or by overcompensation of sensitivity 
variations at the edges of the field. Use of bed displace- 
ment of 1/2 the field of view interval does not prolong 
the acquisition time as sampling remains homogeneous 
over the whole body. 
Attenuation correction is necessary for quantitative 
tracer uptake determination [63, 64]. It is usually per- 
formed using transmission images. These are most nec- 
essary over the thorax, where important variations in tis- 
sue density are expected [65, 66]. Transmission data are, 
however, less critical over the brain and the abdomen. In 
these regions, attenuation can be calculated using body 
contours assuming a uniform tissue attenuation. Errors 
resulting from this assumption may be less critical than 
errors resulting from incorrect attenuation measurements 
by inadequate (short, count deficient) transmission 
scans. Similar considerations have prompted the intro- 
duction of transmission image segmentation for attenua- 
tion correction in the thorax. Segmentation traces the 
contours of the patient as well as of the imaging table. It 
determines the limits of the lungs and optionally of the 
spine and substitutes a known attenuation coefficient for 
the measured attenuation correction. This approach de- 
creases the artefacts produced by the statistical noise in 
the transmission image and allows a reduction in trans- 
mission imaging time. Routine attenuation correction is 
usually not performed in the whole-body mode and such 
an approach may be necessary for its routine implemen- 
tation. 
Currently quantitative data are usually obtained using 
detailed ynamic imaging followed by static imaging us- 
ing pre-injection attenuation correction [67]. Another 
technique introduced to optimize acquisition time and 
scanner utilization is the use of post-injection and post- 
emission transmission corrections. This approach is 
made possible by the use of a rotating rod source [68]. 
Knowledge of the position of the source allows exclu- 
sion of most of the emission events whose line of coinci- 
dence is not co-linear with the source. The rate of 
emission events co-linear with the source can be estimat- 
ed by the use of a mock transmission source positioned 
at a fixed angle from the real source and a similar event 
rate can be subtracted. This approach as been validated 
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Fig. 1. Normal distribution ofFDG up- 
take 
by phantom and patient studies. It allows significant 
shortening of total patient ime in the scanner and de- 
creases considerably motion artefacts in attenuation cor- 
rected images [69]. 
A high-energy single-photon emitter (cesium-137, 
667 key) has been proposed as a transmission source to 
increase count rate to the distant crystal [63]. Saturation 
of the nearby crystal is no longer a problem as true coin- 
cidence imaging is not perlbrmed ("coincidence" is be- 
tween the source position and its interactions on a dis- 
tant detector) and the near detectors are protected by 
shielding. Preliminary results indicate a considerable r - 
duction in transmission acquisition time using this 
system. Another approach is the use of computed to- 
mography to measure the transmission data. Technologi- 
cal advances have reduced the cost of CT and hybrid 
machines are now being considered. In addition, this ap- 
proach could provide optimal matching between ana- 
tomical and biochemical images. 
Visual qualitative assessment of whole-body PET im- 
aging is usually quite satisfactory [70]. Yet quantifica- 
tion is desirable. The rate of tracer uptake over time can 
be determined using dynamic images. If the blood tracer 
activity over time is also available [obtained by arterial 
sampling or in a large vessel region of interest (ROD], a 
compartmental modelling tracer kinetic approach can be 
used [32]. A three-comparment model is usually used 
with FDG. The Patlak-Gjedde graphical approach can 
also be applied using dynamic data to estimate the rate 
of influx of FDG in quantitative terms [71]. Both ap- 
proaches require assumptions regarding the lumped con- 
stant. Yet this has not been assessed in tumours and 
would be difficult to determine given tumoral uptake 
heterogeneity. 
Simple semi-qualitative analysis is now frequently 
performed using tumour to non-tumour uptake ratios or 
preferably by determining the standardized uptake ratio 
(SUV), which relates the concentration i the tumour to 
the average concentration i the body considered as uni- 
ty. Generally the higher the value, the more likely it is 
that tumour is present. Conceptually simple, the SUV is 
more difficult to apply to whole-body than static imag- 
ing as its requires multiple corrections (for decay, atten- 
uation, scatter, randoms, dead time, etc.) [70, 72-75]. 
Yet it remains poorly standardized as it is still dependent 
on many factors including glucose level, weight and fat 
body content, time after injection, ROI size and scanner 
resolution (partial volume effect) [76-78]. The SUV ris- 
es over time in most untreated tumours and standardiza- 
tion of imaging time is important in quantitative studies. 
SUVs from different institutions with different scanners 
or imaging protocols cannot necessarily be compared. 
The normal distribution of the tracer is illustrated in 
Fig. 1. The uptake predominates in the brain, where the 
grey matter avidly concentrates FDG irrespective of the 
metabolic onditions. Myocardial uptake is variable and 
depends on substrate availability. The kidneys concen- 
trate and eliminate FDG, which therefore accumulates in
the urinary outflow tract and bladder. Moderate uptake is 
noted around the eyes, mainly in the oculomotor mus- 
cles, in the mucosal, muscular and lymph node tissue of 
the mouth, nasopharynx and pharynx, and in the liver, 
spleen and bone marrow. Activity varies markedly in the 
gastrointestinal tract. Some increase is usually noted in 
the region of the stomach, but colonic uptake can be 
quite significant, mainly around the hepatic and splenic 
angles and in the sigmoid [79, 80]. Muscular activity is 
also quite variable [77] and can be prominently in- 
creased in the case of muscle tension or utilization 
around the time of injection. Complete rest (no walking, 
no reading, no chewing, no speaking) is indicated and 
the use of diazepam may be necessary in some tense 
subjects to avoid muscle uptake artefacts. Uptake is low 
in fat tissue. Uptake in the lung is also low but appears 
elevated on images without attenuation correction be- 
cause of the low pulmonary density. Also the activity of 
the skin is overestimated onuncorrected images but may 
provide a convenient landmark for image interpretation. 
Image artefacts can result from technical defects, trans- 
mission image misalignment, patient motion or the pres- 
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ence of an artefactual or normal hot spot on the image. 
They can frequently be prevented by careful attention to 
patient preparation. The patient should be fasting for a 
minimum of 4-6 h before the injection time to reduce 
serum insulin levels to near basal quantities. Water is 
permitted, however, to promote diuresis, and coffee 
might in fact increase fatty acid level and decrease myo- 
cardial uptake (Maisey, personal communication). 
We recommend the i.v. cannular administration f be- 
tween 100 and 400 Mbq of FDG in order to minimize 
the risk of extravasation a d lymphatic migration. The 
injection site is chosen away from expected pathologic 
zones. As mentioned earlier, the patient should be in 
complete rest at the time of injection and during the 
waiting period. We routinely perform scanning 
60-90 min after injection to increase tumoral to back- 
ground contrast. This delay also allows better emptying 
of the urinary tract and voiding of the most concentrated 
urine before scanning. Imaging of the pelvis neverthe- 
less presents ignificant problems, and forced diuresis 
(using 20 mg i.v. furosemide) is in our opinion neces- 
sary. The bladder should be emptied before the examina- 
tion to eliminate the concentrated urine but we prefer to 
work with a bladder full of weakly concentrated urine 
whose spherical limits are clearly recognized rather than 
with an "empty" bladder whose activity cannot be pre- 
cisely delimited. Often patients receiving diuretics re- 
quire bladder catheterization to tolerate the duration of 
the scan. In these cases, we empty the bladder 10 min 
before scanning the pelvic area, then clamp the line and 
let the bladder fill until scanning. Typically scanning is 
started from the inguinal region upwards to minimize 
bladder activity. Artefacts from hot spots also result 
from the use of fittered backprojection algorithms for 
image reconstruction. They can be significantly reduced 
by the use of iterative reconstruction algorithms. The in- 
crease in computing power facilitates the use of these 
technique nowadays and they are recommended spe- 
cially in the pelvis. Image interpretation can also be 
markedly facilitated by image fusion. The concomitant 
analysis of metabolic and structural information pro- 
vides anatomical references frequently lacking in PET 
and a more precise estimation of lesion size, which is 
frequently a critical parameter in image interpretation 
(for instance to estimate the influence of the partial vol- 
ume effect) [81]. 
Clinical indications for FDG in oncology 
Let us first examine the clinical indications for FDG im- 
aging as they present along the course of the cancerous 
process [6, 62, 82-86]. We shall later discuss these indi- 
cations in detail, tumour by tumour. 
!645 
Differential diagnosis 
FDG PET has proved useful in the differential diagnosis 
of the solitary pulmonary nodule, the differentiation of
pancreatic arcinoma versus mass-forming pancreatitis 
and the diagnosis of breast carcinoma in selected cases 
of mammography and/or biopsy failure (in particular in 
dense breasts and in implants). In other indications, uch 
as the differential diagnosis of thyroid cancer in patients 
with cold nodules, PET may not be cost effective in 
comparison with a standard iagnostic strategy. 
Initial (preoperative) staging of cancer 
The importance of initial staging for optimal cancer 
management cannot be overemphasized. The success of 
therapy indeed depends on adequate staging. The role of 
diagnostic techniques in staging is, however, variable 
and depends on the efficacy of the screening methods for 
that cancer, on the propensity of the tumour for early 
metastases and on the role of surgery itself in staging. 
Initial staging by FDG has proven useful in lung cancer, 
melanoma nd sarcoma. Initial staging in lymphoma is
probably indicated as a baseline for therapy follow-up. 
FDG PET staging is also probably indicated in selected 
cases of other tumour types, especially when the tumour 
is at an advanced stage or when metastatic lesions are 
suspected by conventional imaging or suggested by high 
levels of tumour markers. Indeed, in these cases, FDG 
PET can provide sensitive whole-body screening. This is 
certainly the case for ovarian, head and neck and pancre- 
atic carcinomas. Initial evaluation in colorectal cancer 
has been suggested, but results are inconclusive. Initial 
staging in breast carcinoma has been the subject of sev- 
eral studies. Although initial results were optimistic, re- 
cent reports in larger non-selected groups of patients 
have suggested that the sensitivity for the detection of 
axillary node metastases is around 75%. FDG PET can, 
however, depict internal mammary node metastases that 
are not routinely explored by the surgeon. At this stage, 
the role of PET in the staging and prognostic evaluation 
of breast carcinoma remains to be clarified. 
Another indication related to initial staging is the 
search for the site of the primary tumour in patients with 
known metastases. According to Kole et al. [87], the 
success rate of whole-body PET in this indication is ap- 
proximately 25%. 
Differentiation of scar and residual disease 
Differentiation of scar and residual or recurrent disease 
is a frequent indication for PET and one of the first to be 
documented [88]. In 1988, Di Chiro et al. showed the 
value of FDG PET in distinguishing radiation ecrosis 
from recurrent tumour in the brain [89, 90]. A similar 
differentiation has been reported to be useful in the 
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lungs and in head and neck turnouts. Indeterminate p l- 
vic masses on CT are frequent in the follow-up of colo- 
rectal cancer and require biopsy evaluation. Strauss et al. 
described the value of PET for distinguishing scar from 
recurrence [91]. The use of an iterative reconstruction 
technique to avoid bladder artefacts was essential in their 
success. FDG has also proven useful in the evaluation of 
residual masses after therapy for lymphoma. Gallium 
has previously been found useful in this indication but 
FDG, unlike gallium, does not require a baseline xami- 
nation to verify that the tumour indeed accumulates the 
tracer. 
Demonstration of suspected recurrences 
Other cases of suspected recurrence occur when tumour 
markers increase or when the patient presents general or 
local clinical signs suggestive of turnout recurrence. Tu- 
mour markers are used routinely to follow up patients 
with colorectal, ovarian, breast, lung, thyroid or pancre- 
atic cancers, etc., and in many cases conventional imag- 
ing fails to detect he recurrence because of its small size 
or its occurrence at a distance from the initial site. Sev- 
eral studies have concentrated on the value of PET for 
the detection of early recurrences in such cases, based on 
its high sensitivity and its whole-body capability. In- 
deed, whenever a recurrence is confirmed, the extent of 
recurrence becomes the next question as the clinician 
ponders the therapeutic options. 
The impact of PET on management, avoiding unnec- 
essary surgery, allowing more complete surgery or al- 
lowing surgery when it had seemed contra-indicated, 
forms the basis of its cost-effectiveness [92]. 
Follow-up of therapy 
FDG PET has been shown to be useful in evaluation of 
the early therapeutic response. FDG uptake can be mark- 
edly diminished or even completely suppressed after one 
or two cycles of chemotherapy, well before tumour mass 
can be shown to have decreased by conventional imag- 
ing. With the use of quantification, this technique has 
wide indications and is of interest for most cancers ub- 
mitted to chemotherapy or radiotherapy (lymphoma, 
breast umours, sarcoma, ovarian turnouts, germ cell tu- 
mours, head and neck carcinomas, lung cancer, colorec- 
tal cancer, hepatic metastases, etc.). Early determination 
of therapeutic resistance is also important o avoid the 
toxicity of an ineffective therapy and to allow selection 
of a new therapeutic regimen. 
Prognostic value of FDG uptake 
The prognostic value of FDG uptake has also been 
stressed by Alavi et al. [93] in cerebral tumours and by 
Reisser et al. [94] in head and neck tumours; tumours 
with higher FDG uptake appear more aggressive and to 
develop faster. The extent of metastatic involvement as 
depicted by PET and the evaluation of the therapeutic re- 
sponse also have prognostic significance. 
Results in selected organs and cancer types 
Lung tumours 
Differential diagnosis. Lung cancer is one of the most 
prevalent cancers in the industrialized world and a lead- 
ing cause of cancer death in both men and women. Lung 
cancer may present as a solitary pulmonary nodule and 
be detected by conventional chest radiography. The inci- 
dence of these nodules is high: 130 000 new cases per 
year in the United States, or 52 cases per 100000 inhab- 
itants. Despite the progress of imaging and in particular 
of computed tomography (CT), few criteria can reliably 
differentiate benign from malignant nodules [95]. The 
generally accepted criteria of benignity are: 
1. Detection of a benign pattern of calcification (central, 
diffuse, popcorn) in the nodule 
2. Stability of the nodule over the preceding 2 years 
3. A very low probability of malignancy, based on age, 
particularly if exposure to tobacco smoke has been 
minimal 
The clinician must therefore frequently choose between 
expectation, potentially dangerous in malignant lesions, 
and invasive diagnostic or therapeutic measures carrying 
high morbidity and also some mortality risk even when a 
benign lesion is present. It is currently estimated that 
50%-60% of solitary pulmonary nodules are benign 
[96]. Yet despite current advances in morphological im- 
aging the number of resected nodules proving benign re- 
mains high (20%-40% of the total), indicating that a 
substantial number of patients are needlessly exposed to 
peri- and postoperative complications [97]. 
Considerable xperience is now available regarding 
the diagnostic value of FDG PET in solitary pulmonary 
nodules. Table 1 summarizes the main reported studies, 
including the date of publication, the number of patients 
studied, and sensitivity and specificity [70, 92, 98-107]. 
As can be seen, a high sensitivity has been achieved by 
all groups (average 96%). The specificity is also high but 
varies slightly more and probably depends on the local 
prevalence of the known causes of granulomatous dis- 
ease responsible for false-positive cases (tuberculosis, 
histoplasmosis, aspergillosis, coccidiomycosis, blasto- 
mycosis, etc.). 
We have prospectively studied 50 patients with unde- 
termined solitary pulmonary nodules. Results of whole- 
body PET (neck to mid abdomen) were correlated to the 
surgical or transthoracic needle aspiration biopsy of the 
lesion (Fig. 2). Thirty-three pulmonary cancers were 
correctly identified while 15 of 17 benign nodules were 
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Table 1. Studies on the use of FDG PET in solitary pulmonary nodules 
Authors Year  Reference No. of Sensitivity Specificity PPV NPV 
pts. 
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Dewan et al. 1993 99 30 95 80 90 89 
Slosman et al. 1993 101 36 93 - - - 
Gupta et al. 1994 103 61 93 85 - - 
Lowe et al. 1994 70 88 97 89 95 92 
Scott et al. 1994 104 62 93 80 - - 
Dewan et al. 1995 105 26 100 78 93 100 
Bury et al. 1996 107 50 100 88 94 100 
Total 317 96 
Multicenter 1994 237 96 90 
Fig. 2. Malignant solitary pulmonary 
nodule (adenosquamous cellcarcinoma). 
Chest X-ray and CT showed an unspeci- 
fied 1.7-cm solitary pulmonary nodule 
recognized. There were two false-positives (one case of 
active tuberculosis and one case of pseudotumoral n- 
thracosilicosis with partial necrosis and perinecrotic in- 
flammation). At present, our positive predictive value is 
94% while our negative predictive value is 100% 
[106-108]. 
Dewan et al. have compared the use of PET with a di- 
agnostic strategy based on CT and transthoracic fine- 
needle aspiration (TTNA) biopsy [105]. In 35 lung le- 
sions PET correctly identified all 26 malignant lesions as 
well as seven of the nine benign lung lesions, but pro- 
duced two false-positive readings. In contrast, TTNA 
was positive for malignancy in 21 lung lesions (five 
false-negative) but did not result in false-positive find- 
ings. The overall predictive accuracy was 94% for PET 
and 86% for TTNA but the latter resulted in a pneumo- 
thorax in 16 patients while nine patients (26%) required 
chest tube aspiration. This complication rate appears 
fairly typical as compared with other reports [109]. 
Use of FDG PET for differentiation of solitary pul- 
monary nodules could lead to significant savings in ad- 
dition to reducing the number of complications during 
management [92, 105]. 
Application of the quantitative technique to the diag- 
nosis of solitary pulmonary nodules has been evaluated. 
It appears effective and certainly increases the objectivi- 
ty of analysis but it does not appear to significantly im- 
prove the diagnosis as compared to visual analysis [64, 
70]. Reproducibility is maximal for SUV (SUV related 
to lean-body mass corrected for blood glucose concen- 
tration) and for K i (slope of the graphical analysis as de- 
fined by Patlak). Parameters derived from compartmen- 
tal modelling have been less reproducible [74]. 
Preoperative staging. In patients with known lung carci- 
noma, the results of staging both within and outside the 
thorax are the key in determining the operability. Dem- 
onstration of a unilateral hilar adenopathy is not a con- 
tra-indication to surgery if the nodes can be resected 
with the primary tumour. By contrast, extensive medias- 
tinal involvement, contralateral lymph node involve- 
ment, and pleural or distant metastases should contra-in- 
dicate surgery due to the surgical morbidity and the poor 
prognosis. 
Several studies have evaluated the role of FDG PET 
for staging lung carcinoma. These studies must be sepa- 
rated into two groups, Some investigators have used fo- 
cal techniques and have concentrated on hilar and medi- 
astinal lymph node staging, while others have used 
whole-body techniques and have evaluated extrathoracic 
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Table 2. Staging of lung cancer by FDG 
PET Authors Reference No. of Sensitivity Specificity Comments 
pts. 
Berlangieri et al. 110 22 90 100 Med. lymph node 
Sasaki et al. 111 9 86 100 Med. lymph node 
Patz et al. 112 21 100 73 Med. lymph node 
Wahl et al. 49 19 82 81 Med. lymph node 
Bury et al. 119 30 85 81 Med. lymph node 
Buchpiguel t al. 114 26 93 83 WB 
Lewis et al. 115 34 199 97 WB 
Valk et al. 117 62 85 93 WB 
Bury et al. 122 61 100 95 WB 
Med., Mediastinal; WB, whole body 
metastases a well (Table 2) [49, 110-119]. The reported 
sensitivity for lymph node staging in non-small cell lung 
cancer varies from 82% to 100% and the specificity 
from 73% to 100%. We have prospectively studied 50 
patients prior to thoracotomy [119, 120]. The prevalence 
of hilar or mediastinal lymph node involvement was 
58%. We have obtained values of 85% (sensitivity) and 
81% (specificity) with a positive predictive value (PPV) 
of 85% and a negative predictive value (NPV) of 81%; 
by comparison, these four figures with CT were 64%, 
68%, 67% and 65% respectively. It is interesting to note 
that CT both underestimated and overestimated the ex- 
tent of disease, so that in comparison PET would have 
contributed both to cancellation and to confirmation of 
surgery as a therapeutic modality. PET in this indication 
appears to supply information currently only partly pro- 
vided by mediastinoscopy. Given the high sensitivity of 
PET for mediastinal staging, a negative result should al- 
low one to proceed to surgery without mediastinoscopy. 
Considering the 15%-20% false-positive rate however, a
confirmatory mediastinoscopy remains indicated in pa- 
tients with less specific uptake patterns (mild uptake, 
moderate uptake and nodal enlargement, or discordant 
PET and CT results). 
Whole-body FDG PET also contributes to significant 
management changes as first assessed by Lewis et al. in 
34 patients [115]. In this study, unsuspected malignant 
metastatic lesions were recognized in ten patients (12 
extrathoracic and eight thoracic sites). Management 
changes were noted in 14 patients. Six (+2) patients 
were classified as unsuitable for surgery while eight pa- 
tients with equivocal findings were found to have single 
PET lesions. A frequent location of suspected metastases 
are the adrenals, where CT detects many non-specific 
abnormalities. PET can confirm or exclude such metas- 
tases effectively [121]. Our own results confirm the data 
of Lewis [122]. We have studied 61 patients by conven- 
tional imaging and whole-body PET for staging of non- 
small cell lung carcinoma. When CT or PET study sug- 
gested metastatic disease, confirmation was obtained by 
biopsy or clinical or radiological follow-up. As com- 
pared to CT, PET correctly changed the N stage in 13 
patients (21%): it increased the stage in six patients and 
decreased it in seven. Presence of metastatic lesions 
(n=28) was confirmed in 19 patients: eight homolateral 
or contralateral lung lesions, six hepatic lesions, four ad- 
renal lesions, five bone lesions, one pleural lesion, three 
lymph node metastases and one skin lesion. All showed 
intense FDG uptake on PET. In contrast to CT, PET cor- 
rectly identified unsuspected extrathoracic lesions at ten 
distant sites in five patients. There were no known false- 
negative distant PET findings. However, there were three 
false-positive distant PET findings (versus seven with 
conventional imaging) corresponding tomoderate uptake 
in inflammatory lymph nodes (two axillary and one 
lung). We believe that the whole-body PET technique 
can improve the diagnostic accuracy in the staging of 
non-small cell lung cancer. 
Valk et al. [117], in a recently reported study con- 
cerning subsets of 76 and 99 patients, also noted that 
PET correctly changed the nodal stage as determined by 
CT in 18 staging evaluations (24%), increasing the stage 
in eight patients and decreasing it in 11, including one 
false-negative. PET changed the metastasis stage in 30 
patients: previously unsuspected distant metastases were 
demonstrated in 11 patients while normal PET findings 
were obtained at distant sites of CT abnormalities in 19 
patients (one false-negative). 
Detection of cerebral metastases. The detection of cere- 
bral metastases i  also possible using FDG PET but a 
dedicated cerebral PET sequence is probably needed. 
Larcos and Maisey [123] have tested the efficacy of a 
supplementary 10-rain brain sequence in patients with 
various malignancies. Cerebral metastases were reported 
in four patients (1.5%), only two of which were unsus- 
pected prior to the PET scan. The authors conclude that 
"routine" screening for cerebral metastases in patients 
with suspected malignancy may not be clinically useful. 
Demonstration ofrecurrences; follow-up of therapy. Ex- 
perience is also available regarding the use of PET to as- 
sess lung tumour response to therapy and in the detec- 
tion of recurrences after successful initial therapy. Abe 
et al. [124] demonstrated that patients judged to have a 
clinically complete response to radiotherapy or chemo- 
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therapy had negative PET results while results remained 
positive in patients with a partial response. Knopp et al. 
as well as Abe et al. suggested that PET results were the 
most reliable indicators of the patient's prognosis when 
compared with clinical parameters and tumour markers 
[124, 125]. Others have also reported a high diagnostic 
accuracy of FDG PET in the detection of tumour ecur- 
rence [113, 126-130]. 
PET in pIeural disease. In a related subject we have also 
shown the value of PET in the assessment of patients 
with malignant or non-malignant pleural effusion [131 ]. 
We have investigated the utility of FDG PET for the 
aetiological diagnosis of pleural disease in 25 patients. 
Sixteen had malignant pleural disease (three primary 
mesotheliomas and 13 cases of metastatic pleural in- 
volvement) while nine had non-malignant pleural dis- 
ease (three benign tumours and six pleural infective pro- 
cesses). All three mesotheliomas nd 11 cases of meta- 
static involvement displayed intense FDG uptake. Two 
patients with metastases and two with infection had 
moderate uptake. Seven patients with benign lesions had 
no uptake. PET appears useful to reduce the number of 
both open pleural biopsies and limited thoracotomies for 
benign pleural disease. Patients without FDG uptake ap- 
pear unlikely to have cancer. Patients with mild uptake 
require biopsy, potentially directed by PET data, for dif- 
ferential diagnosis. In patients with intense uptake, the 
PET data can also be used for biopsy guidance for histo- 
logical confirmation when needed. 
Similar data have been reported by Lowe et al. [132] 
in 23 patients with biopsy-proven diagnosis. Six patients 
had benign pleural abnormalities, including four with 
SUR values below 2.5. Of 17 patients with malignant 
disease, 15 had SUV values above 2.5. Two patients 
with active infection in the pleural space also had in- 
creased FDG uptake. 
The role of FDG PET in patients with small cell lung 
carcinoma has only rarely been discussed. FDG never- 
theless appears to have some potential role in differenti- 
ating limited disease from extensive disease as well as in 
the follow-up of therapy [125]. 
In summary, results in lung cancer provide evidence 
for many different clinical indications for FDG PET at 
the various stages of the disease, including differential 
diagnosis of solitary nodules, initial preoperative staging 
of the nodal extent of non-small cell lung cancer, detec- 
tion of unsuspected metastases, differentiation or dem- 
onstration of suspected recurrence, and therapeutic fol- 
low-up [133-136]. 
Tumours of the gastro-intestinal tract 
Colorectal carcinoma 
Colorectal carcinoma is a frequent umour and presents 
successive diagnostic problems at the time of initial di- 
1649 
agnosis, staging and assessment of recurrence following 
therapy. 
About 70% of patients have resectable tumours ini- 
tially but recurrences do occur in one-third of patients, 
most commonly during the first 2 years after operation. 
Such recurrences can be locoregional, but more often 
distant or generalized metastases occur and currently on- 
ly about one-quarter of patients with recurrences can be 
cured by re-intervention [ 137]. 
The techniques available for the staging and assess- 
ment of potential recurrences lack sensitivity and preci- 
sion and frequently result in diagnostic and therapeutic 
delays. Tumour markers, although useful, have only a 
59% sensitivity and an 84% specificity for recun'ences 
[138]. Barium enema detects local recurrence but is in- 
sensitive (49%) for overall recurrence detection [139]. 
Similar results are reported for colonoscopy. CT is use- 
ful for liver metastases but not nodal involvement [140]. 
Numerous patients with negative CT have a non-resect- 
able tumour at the time of surgery. 
FDG is avidly concentrated in colorectal carcinoma 
and current studies indicate an important role of PET in 
the evaluation of this cancer. The first report dates back 
to 1982, when liver metastases of colorectal cancer were 
visualized in a feasibility study of FDG and PET at 
Brookhaven National Laboratory [141]. Since then a 
number of studies have been published, confirming the 
value of the technique. 
Preoperative detection and staging. Detection of the pri- 
mary tumour at the time of diagnosis appears possible 
but insufficient data exist to suggest that PET might play 
a role in staging at that time although it has an accuracy 
superior to that of CT [142, 143] (PPV is 93% and NPV 
50% for FDG PET versus 100% and 27%, respectively, 
for CT) [142]. Rather, the clinical and economic impact 
of PET appears more clearly in the evaluation of postop- 
erative recurrence. 
Detection of locoregional recurrences. Patients with pre- 
sacral masses and suspected local recurrences were first 
studied by the group from the German Cancer Research 
Centre in Heidelberg. In several successive studies, these 
investigators [91, 144] demonstrated the value of PET in 
differentiating scar tissue and tumour in this setting, a 
finding later confirmed by Ito et al. and Schiepers et al. 
[145, 146] (Table 3). In contrast, when a presacral mass 
Table 3. Local pelvic recurrence: comparison of FDG PET and 
CT (data from Schiepers et al. [146]: 74 patients, 45 positive 
cases) 
Sensitivity (%) Specificity (%) 
PET 93 97 
CT 60 72 
PET: 2 false-negatives, 1 false-positive and 1 indeterminate 
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Table 4. PET in colorectal carcinoma: stag- 
ing of recurrent disease after initial therapy Authors Reference No. (pts., sites) Sensitivity (%) Specificity (%) 
Gupta et at. 149 18 100 86 
Multicentre 155 59 93 78 
Schiepers et al. 146 76 94 98 
Pounds et al. 151 57, 78 95 87 
Daenen et al. 154 19, 29 95 67 
is identified on CT, it is very difficult to diagnose its ori- 
gin: scar, fibrotic tissue or tumoral recurrence. Biopsy is 
needed but is only useful when positive as false-negative 
results are frequent and due to unavoidable sampling er- 
rors [147]. 
Transrectal ultrasonography (US) can demonstrate 
the depth of involvement of distal lesions as well as the 
presence of pararectal adenopathies. PET in this indica- 
tion appears very useful and clearly superior to CT (95% 
diagnostic sensitivity) but it has not been systematically 
compared with rectal US [91, 146]. It has the advantage, 
however, that the pelvic study is only one part of the 
whole-body survey. 
Staging of patients with suspected or demonstrated re- 
currences. Results demonstrating the value of FDG PET 
in the identification of patients with isolated resectable 
lesions and in distinguishing them from patients with 
disseminated metastases have came from the group in 
Leuven, using the PET whole-body technique. Schiepers 
et al. evaluated 76 patients presenting with or suspected 
of having recurrent local or distant colorectal cancer 
[146]. The accuracy of PET for focal disease was 95%, 
showing it to be superior to CT of the pelvis (65%). The 
accuracy of PET for liver metastases (98%) compared 
favourably with that of CT or US (93%). Unexpected ex- 
trahepatic metastases were detected in 14 locations in 
ten patients. In a previous study on 35 patients, Beets et 
al. from the same group, evaluated the clinical impact of 
PET on management [148]. Sixteen patients presented 
with "resectable" metastases, eight with resectable pel- 
vic recurrences, eight with a presacral mass of uncertain 
nature and three with an isolated increase in the carcino- 
embryonic antigen (CEA) level. PET affected the man- 
agement decision in 7 of the 16 patients with metastatic 
disease; it detected additional esions in two patients 
with pelvic recurrences as well as the site of the disease 
in two of the patients with an increased CEA level. 
Overall, PET affected management in 14 of the 35 pa- 
tients. Falk et al. [142], Gupta et al. [149, 150], Pounds 
et al. [151] and Bohdiewicz et al. [152], as well as data 
from our own group [154], have also stressed the value 
of whole-body PET for staging recurrent disease in colo- 
rectal carcinoma (Table 4). 
A multicentre study organized by the Institute for 
Clinical PET has examined the issue of cost-effective- 
ness in colorectal carcinoma based on a survey of 14 
PET centres and a review of 267 colorectal cancer pa- 
tient records [155]. This preliminary report suggests a
large potential saving based on the elimination of ex- 
ploratory laparotomies and on a reduction (from 20% to 
10%) in the number of resections with curative intent 
(Fig. 3). 
Evaluation of therapy. In 1991, Haberkorn et al. [156] 
evaluated patients with known recurrent disease prior to 
and after radiotherapy. FDG tissue levels tended to fall 
after therapy but changes in uptake parameters were not 
able to accurately predict therapeutic responses in indi- 
vidual patients. The authors uggested the potential role 
of radiation injury and of the inflammatory reaction in 
these results. Inflammation and metabolically active re- 
sidual turnout issue cannot be distinguished early after 
therapy. 
In another eport in 21 irradiated patients, Engenbart 
et al. [157] found that residual FDG uptake indicated the 
presence of residual tumour and a poor therapeutic re- 
sponse. PET was the earliest indicator of local relapse. 
The use of 18F-5-fluorouracil in the therapeutic evalua- 
tion of patients with colorectal cancer is beyond the 
scope of this review. 
Pancreatic arcinoma 
Among gastro-intestinal cancers, pancreatic arcinoma 
has the worst prognosis. This may result from the diffi- 
culties encountered in the diagnosis of this cancer, which 
manifests only with non-specific linical symptoms and 
with indirect signs on routine structural imaging (CT or 
US) [158, 159]. Many nuclear medicine techniques have 
been proposed in the past to visualize the pancreas but 
studies performed with amino acids or blood flow trac- 
ers lack specificity for tumour visualization. Indeed, 
these tracers also accumulate in the normal pancreas and 
cancerous lesions usually appear as cold spots. Lesions 
of other aetiologies, however, also correspond to cold 
spots and this finding is not specific [160-162]. 
Several groups, predominantly from Japan and Ger- 
many, have evaluated the role of FDG PET in the differ- 
entiation of pancreatic adenocarcinoma from benign 
chronic pancreatitis and mass-forming pancreatitis 
[163-169]. Results indicate a sensitivity of ca. 94% with 
a specificity varying from 78% to 90% (Table 5). The 
optimal SUV cut-off varies between studies but is rather 
low (ca. 2) as glucose uptake in the normal pancreas is 
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Fig. 3. Local relapse of previously oper- 
ated rectal carcinoma. PET also demon- 
strates lung metastases 
Table 5. FDG PET evaluation i pancreatic 
tumours Authors Reference n Sensitivity(%) Specificity(%) 
Bares et al. 163 40 92 84 
Inokuma et al. 165 46 94 82 
Friess et al. 164 80 94 88 
Stollfuss et al. 168 73 95 90 
also low. On rare occasions, uptake in the site of pancre- 
atitis is markedly elevated; generally, however, it is only 
slightly higher than in normal controls. Visual criteria 
use discrete focal elevated uptake as evidence for cancer, 
while diffuse or background level activity is taken as ev- 
idence for chronic pancreatitis or normal tissue. Bares et 
al. [163] first commented on the importance of adequate 
blood glucose control for optimal FDG uptake by the tu- 
mour. Indeed, glucose competes with FDG for transport 
and a high level of plasma glucose could inhibit FDG 
uptake within the tumour. Bares suggested this competi- 
tion to be a possib][e cause of false-negative r sults, but 
the four patients with false-negative findings reported by 
Stollfuss did not have diabetes or elevated glucose levels 
[163, 168]. 
Evidence of metastatic extension of pancreatic arci- 
noma, lymph node involvement or liver metastases can 
be appreciated on PET images. However, no systematic 
study has yet been reported on the value of PET in this 
indication. 
Gastric and oesophageal tumours 
Little information is available on the role of FDG PET in 
the evaluation of gastric and oesophageal tumours [150, 
170, 171]. In our limited experience, the ability of FDG 
PET to visualize the primary tumour is excellent. Its val- 
ue in assessing the extent of the disease, progression to 
contiguous tructures, nodal involvement or hepatic me- 
tastases has not been systematically examined yet, to our 
knowledge. 
Liver metastases and hepatomas 
Cancers of the digestive tract, colorectal carcinoma, pan- 
creatic cancer, gastric or oesophageal tumours and can- 
cer of the biliary tract demonstrate a high prevalence of 
haematogenous liver metastases, as do breast cancer, 
ovarian cancer, lung cancer, etc. Current diagnostic mo- 
dalities (mainly US and CT) have suboptimal accuracy 
and many studies are reported as inconclusive [172]. Bi- 
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Table 6. FDGPET evaluation fliverme- 
tastases Authors Year Reference No. Sensitivity (%) Specificity (%) 
Gupta et al. 1993 175 14 92 - 
Shields et al. 1995 176 8 100 - 
Schiepers et al. 1995 146 80 94 100 
Hustinx et al. 1996 177 62 97 87 
phasic spiral CT with images of the arterial and venous 
phase has shown promise for hepatocellular carcinoma 
and might be more useful in detecting hepatic metastases 
[173, 174]. Magnetic resonance imaging (MRI) may 
also be more sensitive than standard CT techniques. 
Several studies have analysed the value of FDG PET 
in detecting liver metastasis (Table 6) [146, 175-177]. 
We have analysed 62 patients with malignant including 
tumours and 30 patients with evidence of at least one 
liver metastasis (histopathological onfirmation i 14 pa- 
tients, clinical confirmation in 16 patients). Negative 
cases were established by pathology (n=4), peroperative 
US (n=12) or clinical follow-up (n=16). Agreement be- 
tween metabolic and structural imaging (CT/US) oc- 
curred in 42/62 patients (68%). FDG was correct in 
15/20 discordant cases. FDG was false-positive in four 
cases and false-negative in one case. 
Schiepers et al. [146] report a 98% accuracy for FDG 
PET detection of liver metastases (of colorectal cancer) 
versus 93% for CT/US (FDG was positive in 33/35 cases 
with metastases, and negative in 48/48 cases without 
metastasis). 
The image contrast between the uptake within liver 
metastases and that in normal tissue increases over time 
as a result of the high level of glucose-6-phosphatase ac- 
tivity within normal liver tissue. This results in de- 
creased 18F radioactivity in normal tissue over time and 
in greater visibility of the lesion [158, 178]. It is there- 
fore appropriate to perform FDG liver imaging in pa- 
tients with suspected liver metastases approximately 
90 min after FDG injection. Attenuation correction re- 
mains possible in these cases if the transmission studies 
are performed after the emission study, as is nowadays 
possible, or if the attenuation correction is calculated us- 
ing the body contour ather than based on transmission 
data. In the latter case, imaging of the patient with his 
arms out of the scanner is essential for adequate perfor- 
mance. 
While delayed imaging improves contrast between 
liver metastases and normal liver, this is probably not the 
case in at least some patients with hepatoma. Indeed, 
while a large fraction of hepatomas are well imaged by 
FDG PET as hot spots relative to the liver, up to half of 
the tumours cannot be detected as regions of increased 
tracer uptake compared with normal iver [34, 179-182]. 
This latter patient group appears to retain a high dephos- 
phorylation rate within the tumour cells. Enomoto et al. 
[180] have suggested that kinetic modelling could be 
used to better characterize hepatoma. In 35 patients with 
liver lesions confirmed by surgery, they analysed tracer 
kinetics using the Sokoloff model [32]. k 3 was correlated 
with tumour hexokinase content and the presence of can- 
cer. Patients with hepatoma nd a high k4/k 3 ratio ap- 
peared to have the best survival. 
Lymphomas 
Several reports have shown the feasibility of imaging 
lymphomas using FDG [183-190]. This approach is of 
particular interest as metabolic imaging does not face the 
difficulties of structural imaging modalities in defining the 
presence and extent of lymphomatous turnouts. CT and 
MRI require perturbation (e.g. space occupation) or en- 
largement (e.g. nodal) of anatomical structure to suggest 
tumour, and abnormal findings lack specificity [185]. 
Limitations of current structural imaging techniques 
appear even more striking subsequent to therapy [184, 
191]. Changes in anatomical indicators are slow and 
may lag behind reduction in the number of viable tu- 
mour cells. Indeed, it appears that fibrosis develops as a 
result of tumour necrosis and initially enlarged tumour 
sites may remain permanently enlarged after effective 
sterilization of the tumour. FDG appears particularly 
useful for the assessment of therapy in patients with 
lymphomas as changes in the metabolic stage of the tu- 
mour appear to reflect more closely viability of the re- 
maining tumour cell mass than tumour volume [189, 
192, 193]. 
Initial staging. FDG imaging in lymphoma was first re- 
ported by Paul [183]. He compared FDG with gallium- 
67 using planar imaging in five patients with non-Hodg- 
kin's lymphoma nd detected abnormalities in four of 
the patients with FDG as compared with two of them us- 
ing gallium. 
Okada et al. reported on 21 and then 23 patients with 
lymphoma of the head and neck regions [36, 187]. Abnor- 
mal PET studies were reported in all patients, while galli- 
um uptake was abnormal in 20 of 21 patients. Low-grade 
lymphomas appeared to have less FDG uptake than higher 
grade lymphomas as a good correlation was obtained be- 
tween FDG uptake and biopsy-obtained stimates of tu- 
mour proliferative rate. It has also been suggested that in- 
creased FDG uptake is associated with a less favourable 
prognosis for the lymphoma patient [194]. 
Leskinen-Kallio et al. [195] also observed that in- 
creased FDG uptake was proportional to the histological 
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Fig. 4. High-grade non-Hodgkin's lym- 
phoma before (left) and after (right) 
chemotherapy 
grade, with the most malignant tumour accumulating the 
most FDG. Some low-grade tumours were not detected. 
Based on studies in 14 patients, the authors suggested 
that 11C-methionine might be superior to FDG in detect- 
ing lymphomas but that FDG was better at distinguish- 
ing tumonr grade. Newman et al. [185] compared FDG 
PET and CT in 16 patients with mixed lymphoma cases. 
PET (not using the whole-body technique) identified 54 
abnormalities in 13 patients compared with 49 by CT. 
Subsequent s udies remained normal in the three patients 
with normal PET scans. Rodriguez et al. [35] also report 
on the role of PET in predicting malignancy grade. 
These limited results suggest he value of FDG for the 
detection of even low-grade tumours. 
Several other abstracts upport he effectiveness of
FDG PET in lymphomas [193, 196, 197]. PET usually 
demonstrates more lesions than CT and this may result 
in patient upstaging (three cases among 26 patients with 
Hodgkin's disease [198]) and in changes in patient man- 
agement. 
We have studied 42 patients with histologically prov- 
en lymphomas [188-200]. Twenty patients had aggres- 
sive non-Hodgkin's lymphoma (NHL), 13 low-grade 
NHL and 9 Hodgkin's disease (HD). Thirty patients 
were evaluated at initial presentation while 12 under- 
went PET for disease recurrence. Evaluation of disease 
extension was performed by PET and compared with 
clinical evaluation (presence of lymph nodes with a min- 
imal diameter of 10 mm or more in the cervical, axillary 
and inguinal regions), with CT (standard size criteria of 
1.5 cm used to define pathology) and with biopsy when 
available. PET detected more lesions than clinical exam- 
ination and/or CT in patients with aggressive NHL or 
HD (9 of 29 patients had more PET sites than clinical 
sites; 3 of 29 patients had more PET sites than CT sites). 
Results were different in patients with low-grade NHL: 
Concordant results were observed in 9/14 patients by 
clinical examination and in 7/13 patients by CT. More 
sites were detected by PET than by clinical examination 
in two patients and more were detected by PET than by 
CT in one patient, while more sites were detected by 
clinical examination i three patients and by CT in five 
patients. These results differ from other eports concern- 
ing low-grade NHL [185, 186]. One possible reason is 
that other reports have concentrated ona single area for 
comparison while this study involved whole-body scans. 
As the uptake in low-grade NHL is lower than in high- 
grade tumour, the sensitivity of the whole-body tech- 
nique with limited scanning time may be insufficient to 
detect all lesions. 
Additionally we have found that PET is valuable for 
the detection of splenic involvement and digestive tract 
infiltration (three of four cases were detected). By con- 
trast, PET does not appear useful for the detection of 
bone marrow infiltration as it cannot differentiate bone 
marrow involvement from non-specific bone marrow 
stimulation or from growth factor stimulation. 
Follow-up of therapy and detection of recurrences and of 
residual disease. We have also assessed the role of FDG 
PET imaging in the evaluation of therapy (Fig. 4). Our 
results concern 55 cases studied for early treatment eval- 
uation (19 patients), end of therapy assessment (18 pa- 
tients) and detection of recurrences (25 patients). Early 
response to therapy (two to three chemotherapy c cles) 
defines a subgroup of patients with good prognosis 
(eight of nine patients have remained in remission 8 
months after the end of therapy) while patients with re- 
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sidual FDG uptake have a poor prognosis (four deaths 
and one case of residual disease among ten patients). 
FDG PET also appears useful in differentiating scar 
from residual disease in patients with residual masses 
and in detecting early recurrences: PET was positive in 
all cases of clinical recurrence (11 patients) while it de- 
tected lesions in three patients with clinical remission 
[2001. 
These results need to be confirmed in larger patient 
groups and with longer follow-up but it already appears 
that FDG could play an essential role in the follow-up of 
lymphoma therapy to confirm the therapeutic choice and 
good prognosis, or, on the contrary, to detect herapeutic 
resistance at an early stage [201,202]. Potentially toxic 
regimens could be stopped early in the latter patients and 
replaced by an alternative regimen. PET could also be 
used to select responders for highly toxic or very expen- 
sive treatment and enhance both the cost-effectiveness of 
treatment and the quality of life in these patients. 
Head and neck carcinomas 
Head and neck carcinomas are associated with the abuse 
of alcohol and/or tobacco and their frequency is increas- 
ing. They take their origin in the superior alimentary and 
respiratory tracts and mainly comprise squamous cell 
carcinoma (90%). Other lesions take their origin in glan- 
dular tissues (mainly the salivary glands) or in lymph 
nodes. Head and neck carcinomas have high glycolytic 
activity and their successful demonstration with FDG 
was reported in the late 1980s with the use of a specially 
collimated gamma camera [202]. Use of l lC-methionine 
has also been proposed in this indication [203,204]. 
Initial diagnosis and staging of head and neck carci- 
nomas is based on clinical examination. This is usually 
quite successful as most tumours are reasonably accessi- 
ble to observation and palpation by the head and neck 
specialist. The clinical examination is usually completed 
by CT or MRI and by biopsy. Palpation has, however, 
been reported to be superior to structural imaging for 
lymph node involvement as the latter is strictly based 
upon the size of the lymph node while palpation assesses 
the node structure and induration [205]. 
PET metabolic riteria offer some advantages over 
anatomical imaging. They can detect superficial or sub- 
mucosal primary tumour infiltration without adjacent tis- 
sue deformation. They can also indicate uptake and in- 
volvement of normal size lymph nodes while showing 
no involvement in some enlarged reactive lymph nodes. 
Evaluation of the accuracy of FDG PET in the diagnosis 
of the primary tumour has been performed to validate its 
potential in this type of tumour ather than to support its 
clinical use in this indication [206-209]. Minn et al. 
were able to image 13/13 cancers using FDG [202]. Bai- 
let et al. [210] identified 16/16 primary lesions using 
PET, including one lesion not well delineated by ana- 
tomical imaging (superficial tumour involving the anteri- 
or tongue). These tumours have a high tumoral to nor- 
mal metabolism ratio as reported in a concomitant paper 
from the same group [40, 211]. McGuirt et al. [212] 
studied 25 patients with laryngeal carcinoma before de- 
finitive therapy. PET identified the primary tumour in 22 
cases. There were one false-negative and two equivocal 
lesions, all in the supraglottic region. McGuirt et al. 
[213] also reported on the identification ofbenign versus 
malignant parotid masses. PET identified all 26 lesions 
and all 12 malignant lesions but made the correct catego- 
rization in only 69% of cases. Indeed, six benign lesions 
(Warthin's tumours, pleomorphic adenomas and a toxo- 
plasmosis adenopathy) presented falsely positive uptake 
[214]. 
In summary, PET is potentially useful in selected in- 
dications in patients with primary ENT turnouts, for in- 
stance to direct the site of biopsy, but cannot be proven 
cost-effective in this setting. 
Definition of lymph node extension in patients with 
ENT tumour is potentially a more useful indication as 
lymph node metastases are frequent in the evolution of 
these cancers and represent the most determinant prog- 
nostic factor [215, 216]. Sixty percent of patients have 
one or more palpable adenopathies at the time of diagno- 
sis while 40% have lymph node metastases. The average 
5-year survival is >50% in the absence but only around 
30% in the presence of lymph node metastases [217]. 
Presence or absence of invaded nodes also determines 
the type of therapy [218, 219]. In particular, the presence 
of contralateral disease in a patient eliminates surgery as 
a treatment option. 
Ballet et al. [220] evaluated 203 lymph nodes from 
eight neck dissection specimens; 17 were positive for 
malignancy. PET accurately diagnosed 12 (71%) of 
these positive nodes, as against en diagnosed by ana- 
tomical imaging. PET was false-positive in three reac- 
tive nodes. McGuirt et al. [212] correlated the neck nod- 
al status in 27 specimens from 17 patients. PET agreed 
with pathology in 22 cases (81%), with three false-posi- 
tives and two equivocal specimens. In a separate study, 
the same authors reported on 49 patients of whom 45 un- 
derwent neck dissection, allowing corroboration of clini- 
cal and imaging results with histopathological d ta. PET 
and CT yielded similar results (82% and 84% accuracy) 
and were superior to clinical assessment (71% accuracy) 
[206]. 
In our experience in 19 patients with surgical and his- 
topathological verification, PET detected all primary tu- 
mours [217]. PET correctly interpreted the absence of 
metastatic lymph nodes in 11/14 patients but there were 
three false-positive r active nodes. PET detected one in- 
volved contralateral lymph node in one patient hat was 
not detected by CT or clinical examination. Finally, PET 
missed two cases of microscopic nodal foci also unde- 
tected by CT and clinical examination. 
Definition of residual or recurrent disease after adio- 
therapy or surgery presents more of a challenge for the 
clinical examination as well as for anatomical imaging. 
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Fig. 5. Local relapse of head and neck carcinoma previously treated by surgery and radiotherapy. CT suggested osteonecrosis of the left 
jaw. Recurrent disease isevident on PET 
The fascial planes can be distorted or destroyed by post- 
surgical scarring or post-irradiation fibrosis and normal 
anatomical structures may be unidentifiable. FDG PET 
appears ideally suited in these indications, as suggested 
by initial reports [221,222] (Fig. 5). 
Greven et al. [223] reported on 18 patients tudied 4 
months after radiotherapy. Eleven patients had a normal 
PET scan at the primary site and none had subsequent 
recurrence. Seven had abnormal FDG uptake and six of 
these had biopsy-proven recurrence. Fifteen patients had 
normal PET at the nodal site and none had recurrences 
while three patients had abnormal PET with evidence of 
biopsy-confirmed nodal recurrences in two. Similarly, 
Ballet et al. [220] compared PET and MRI in ten pa- 
tients with recurrent tumours 4 months to 4 years after 
radiotherapy. PET determined recurrence in all patients 
while MRI was negative or inconclusive and clinical ex- 
amination was frequently non-specific. A comparative 
study of FDG SPET and thallium was reported by Mu- 
kherji et al. [224]. 
FDG PET has also been used to monitor tumour re- 
sponse to various chemotherapy or radiotherapeutic regi- 
mens. According to Chaiken etal. [225], elevated or ris- 
ing FDG PET activity after radiation therapy was indica- 
tive of persistent or recurrent disease in 89% of cases 
(8/9) while a significant decrease in activity was ob- 
served in patients in whom local control was achieved. 
Greven etal .  [223, 226], however, did not believe that 
early PET scan (1 month) accurately reflects the status 
of disease and recommended a minimum delay of 4 
months. These studies extended previous work by Minn 
et al. [202] and Haberkorn etal. [227], who documented 
a significant decrement in uptake ratio after irradiation 
among radioresponsive but not radioresistant tumours. 
Similarly, tumours appear more sensitive to chemothera- 
py than lymph nodes [228]. 
Prognosis. As suggested by Reisser et al. in 50 patients, 
FDG uptake before therapy can predict prognosis [94, 
229]. Patients with an SUV above 3-4 (300%-400%) 
had a less favourable prognosis than patients with a low- 
er SUV value. 
Breast cancer 
Breast cancer is the most frequent malignant tumour in 
women of Western countries [230]. The most frequent 
form is an adenocarcinoma of the endothelial cells of the 
galactophorous ducts. It is primarily localized in the ex- 
ternal upper quadrant (50%), in the internal upper quad- 
rant or in the central regions. Breast cancer is in many 
cases a systemic disease. Indeed, disease recurrence is 
metastatic rather than locoregional in nine of every ten 
cases. Metastases appear early in the course of the dis- 
ease while the tumour growth rate is slow (doubling 
time: 1-3 months; a tumour eaches 1 cm after 5 years 
and 2 cm after 10 years) [231-233]. 
Local extension is along the galactophorous ducts to 
the nipple and the remaining land, skin and deep tis- 
sues. Breast carcinoma is frequently multicentric (30%) 
or bilateral (7%). Locoregional extension is via the lym- 
phatic system and carries important prognostic value. 
Nodal metastasis found in 60% of patients at the time 
of diagnosis and the 5-year recunence-free survival is 
75%, 45% and 20% with involvement of no, one to 
three, and more than three axillary nodes, respectively. 
Mortality is also clearly related to the presence or ab- 
sence of metastasis [234]. The primary lymph pathway 
is by contiguity along the external mammary pedicle to 
the first, second and third axillary groups from the exter- 
nal superior quadrant. The central and internal quadrants 
also carry lymph to the internal mammary node groups 
(between the second and third intercostal spaces). From 
these, extension to the sub- and supraclavicular g oups, 
upper mediastinal groups and contralateral axillary 
groups is possible. Systemic metastatic extension is hae- 
matogenous and primarily affects the axial skeleton, the 
liver, the lung and the pleura. The brain, ovaries, adre- 
nals and skin are less frequently involved. 
European Journal of Nuclear Medicine Vol. 23, No. 12, December 1996 
1656 
Table 7. Breast carcinoma - nodal extent 
Authors Reference No. of Sensitivity Specificity Acquisition technique 
pts. (%) (%) 
Wahl et al. 246 7 100 Attenuation corrected 
Tse et al. 243 10 57 100 Whole-body 
Adler et al. 251 20 90 100 Attenuation corrected 
Hoh et al. 83 14 67 100 Whole-body 
Avril et al. 253 18 72 96 Attenuation corrected 
Nieweg et al. 249 5 100 - Attenuation corrected 
Multicentre 257 49 96 96 Various 
Several other prognostic indicators have been recog- 
nized beyond nodal extension: primarily the size of the 
tumour, the presence or absence of local inflammatory 
signs, the presence or absence of hormonal receptors 
[235-237] (progesterone r ceptors have greater prognos- 
tic value than oestrogen receptors) and the age of the pa- 
tient (women under 35 years have twice the rate of axil- 
lary involvement as older women). The histopathological 
classification based on the degree of differentiation 
(SBR grades I-III) also carries prognostic information 
[238], as do more recently developed oncogene-related 
markers [239]. 
Diagnosis. Initial therapy is decided upon based on the 
results of staging and of the prognostic evaluation. The 
role of PET and in particular of FDG PET in the diagno- 
sis and management of breast carcinoma has been the 
subject of several studies [240-244]. Several groups have 
reported a high degree of success in detecting the prima- 
ry tumour. Although the first feasibility studies included 
only small numbers of patients with large tumours, larger 
more representative series have now been reported 
[245-248]. Using a whole-body imaging technique, Hoh 
et al. [83] detected 15/17 primary breast carcinomas. Ni- 
eweg et al. [249, 250] identified 10/11 primary lesions. 
Adler et al. [251,252], in a prospective study, recognized 
26/27 malignant lesions. While other studies are forth- 
coming (some of them are already available in abstract 
form) that will confirm the high sensitivity of PET for the 
detection of the primary lesion, it should be noted that 
most studies have evaluated breast masses of more than 
1.0 cm in diameter and that the sensitivity of the method 
for definition of small cancers remains to be established 
[81,253]. Also the method's pecificity has not been ful- 
ly determined in a large number of benign lesions. There- 
fore current results must still be considered preliminary. 
The need for a new technique in the primary diagnosis of 
breast tumours must be weighed against he sensitivity 
and cost of current modalities. There appears to be little 
space for FDG PET, given the role of mammographic 
screening and confirmation by needle or surgical biop- 
sies. One potential area of application, however, is in pa- 
tients with silicone implant augmentation mammopla- 
sties, as reported by Wahl [254]. Use in patients with 
dense breasts or in patients with unsuccessful needle bi- 
opsy has also been suggested. 
Nodal extension. Evaluation of axillary nodal extension 
could prove a more practical indication for FDG PET. 
Indeed, it could potentially replace axillary lymph node 
dissection (ALND). ALND is currently performed for its 
prognostic value only, yet carries significant morbidity 
and cost [234, 255, 256]. Complications include postop- 
erative seroma formation, arm oedema, breast oedema, 
nerve injuries and shoulder dysfunction. ALND can sig- 
nificantly prolong hospitalization, anaesthesia and post- 
operative care or be a separate procedure when associat- 
ed with breast conservation therapy. 
The current incidence of patients with positive node 
dissection among those receiving partial mastectomies 
has dropped to 25% in some reports (probably due to ear- 
lier detection). As calculated in an ICP report, a sensitivi- 
ty and specificity of 90% and 95% respectively would 
have an NPV of 97% and spare 33 patients the morbidity 
of ALND at a cost of missing one patient with lymph 
node involvement [257]. More conservative estimates of 
sensitivity and specificity (75% and 90% respectively) 
would result in an NPV of 92% and spare 25 patients the 
morbidity of ALND at the cost of missing two patients 
with lymph node involvement. As suggested by the au- 
thors of the ICP report, even this higher error rate may be 
justifiable given the limited improvement in survival that 
would be expected from chemotherapy [257]. 
Initial results of PET in patients with advanced breast 
carcinoma demonstrated a high rate of detection of 
lymph node metastases. Results in subsequent studies 
have varied from 67% [83] to 90% [251] but the number 
of patients studied remains low and results appear to 
vary in part with the technique used (sensitivity is poten- 
tially higher using an attenuation-corrected static scan 
than with a whole-body non-attenuated technique) (Ta- 
ble 7). Recent results and our own experience suggest a
75%-80% sensitivity with good specificity (96%) [253]. 
If larger studies in stage I or II breast cancer patients 
confirm both the sensitivity and the specificity of PET 
and a low incidence of lymph node metastases (<30%) 
to yield a high NPV (>90% or preferably >95%), PET 
could replace ALND in these patients. As mentioned 
earlier, PET also has the potential to detect internal 
mammary lymph node metastases and this should be a 
significant advantage in patients with central or internal 
quadrant tumours. Unfortunately, no data have yet been 
reported on the clinical impact of this feature. 
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Fig. 6. Hilar mediastinal nd right axil- 
lary nodal metastases from breast cancer 
before (superior pannel) and after (infe- 
rior pannel) two courses of chemothera- 
py (Taxotere) 
Metastatic staging. PET also has the potential to detect 
distant metastases, e.g. in the liver, skeleton or more dis- 
tant nodal chains. Such metastases will radically alter 
patients' management. In this context he use of whole- 
body PET could potentially replace the need to perform 
a conventional metastatic survey including CT, US and 
conventional skeletal scintigraphy [258]. Available data 
point to the value of PET in this indication but it has not 
yet been tested in specific patient groups, such as pa- 
tients with stage III breast cancer at the time of initial di- 
agnosis, or later on in the disease, eog. in patients with 
suspected recurrences [246, 249, 250, 259]. 
Therapy follow-up. Finally, a number of reports have as- 
sessed the role of FDG and PET in assessing response to 
breast cancer therapy (Fig. 6). Wahl et al. studied 11 
women with newly diagnosed primary breast cancer 
larger than 3 cm in diameter and undergoing a chemo- 
hormonotherapy rogramme [59]. These patients had 
one baseline and four follow-up quantitative PET scans 
to test the feasibility of non-invasive metabolic therapy 
monitoring. Tumour uptake decreased rapidly in eight 
patients with partial or complete response while it did 
not change in non-responders. The metabolic response 
preceded ecrease in tumour size. Furthermore, ffective 
chemotherapy, when repeated, leads to diminution of 
glucose uptake levels to basal values while FDG uptake 
increases in patients receiving inefficient herapy. Re- 
ports from Nieweg et al. [250], Chaiken et al. [225] and 
Jansson et al. [260] also suggest a role for PET in the 
follow-up of therapy. 
We have used FDG PET in ten patients considered for 
bone marrow transplant. Evaluation of the disease xtent 
before chemotherapy and of the initial results after two 
to three therapy courses has helped us to identify re- 
sponders, who were submitted to transplant after full 
therapy, and non-responders, in whom the approach was 
discontinued to prevent further unnecessary bone mar- 
row toxicity. PET evaluation of early therapy response 
could also be used to individualize drug selection in dif- 
ficult cases. 
Melanoma 
Melanoma is a cutaneous malignancy whose frequency 
is increasing. It has a high mortality related to its pro- 
pensity for early nodal metastasis and hematogenous 
visceral spread. Between 20% and 40% of patients with 
clinically localized lesions have nodal metastases found 
at surgery. Although sentinel node biopsy offers promise 
in the detection of such patients with minimally invasive 
surgery [261], a technique to non-invasively detect the 
presence of involved nodes would obviously be of value. 
Also in treated patients, detection of recurrences or of 
metastases is made difficult by the wide range of poten- 
tial hematogenous spread of the tumour. This requires 
regular chest, abdomen, pelvis and brain CT or MRI, as 
well as confirmatory procedures in cases of indetermi- 
nate or suspicious results [262]. 
Staging. In animals, melanoma is one of the tumours 
with the highest glycolytic metabolism and FDG uptake 
[263]. Initial evaluation confirms the high sensitivity of 
FDG PET in detecting melanoma lesions. Gritters et al. 
performed limited area scanning in 12 patients in regions 
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of the body having or suspected to contain malignant 
melanoma on the basis of physical examination and pri- 
or imaging data [264]. In superficial lymph nodes, PET 
correctly identified 7/7 metastastic lymph nodes (includ- 
ing three normal size lymph nodes) and correctly pre- 
dicted the absence of tumours in 6/6 lymph nodes (accu- 
racy 100%). The sensitivity of PET was also very high 
for intra-abdominal visceral metastases (15/15) ranging 
in size from 0.5 to 8.0 cm. Five of these lesions were on- 
ly seen on CT retrospectively or several months later. 
PET, however, was much less successful in detecting 
pulmonary metastases (4 of 27 lesions in four patients) 
but most of the lesions were under 1 cm in size. 
Steinert et al. [265a, 265b] reported on the role of 
whole-body PET with FDG in staging malignant 
melanoma in 33 patients. Twenty-three had known meta- 
static disease while ten had a newly diagnosed melano- 
ma with a high risk of metastases (Breslow thickness 
>1.5 mm). Of 55 evaluated lesions, 40 proved to be 
metastatic. PET correctly identified 37 sites but missed 
three small (<3 mm) cutaneous metastases. It depicted 
metastases in six patients and excluded malignancy in 
ten suspicious ites. Specificity evaluated in ten enlarged 
benign lymph nodes and three inflammatory lesions was 
100% using marked uptake criteria or 77% using mild 
uptake criteria (concomitant sensitivity varied from 73% 
to 92%). In this study PET detected three of 3 thoracic 
lymph nodes, albeit with mild intensity only in two 
cases. 
Other studies and abstracts confirm the high sensitivi- 
ty of FDG PET [266-268]. Kirgan et al. [269] demon- 
strated more lesions with PET than with CT or MRI in 
16/24 patients, with PET leading to a change in manage- 
ment in 45% of cases; in half of these, surgery was can- 
celled as more extensive disease was present than previ- 
ously appreciated. Yao et al. [270] assessed the value of 
PET in initial staging as compared with other modalities 
in 31 patients. In 18 of these, PET provided new infor- 
mation and in ten it provided comparable information to 
all other studies combined, while in three patients it was 
less effective. The latter cases were brain metastases 
missed by the whole-body PET acquisition, but in a sep- 
arate substudy brain acquisition did not miss brain le- 
sions. 
Therapy assessment. Strauss et al. [266] studied the ef- 
fect of chemotherapy on FDG uptake in patients with 
melanoma. A slight reduction was seen at 90 min but a 
greater reduction occurred at 48 h, persisting for 1 week. 
The degree of FDG uptake reduction correlated irectly 
with the subsequent clinical response. 
In conclusion, whole-body PET with FDG appears to 
contribute importantly in the staging of patients with 
melanoma. It can detect superficial lymph node or skin 
lesions down to 0.5 cm or less and has high sensitivity 
for visceral metastases with the possible exception of 
pulmonary lesions. It could serve as a cost-effective one- 
modality follow-up technique in patients at high risk of 
recurrence or metastasis. Its role in detecting nodal 
spread early after initial detection of the melanoma p- 




Diagnosis. Thyroid cancer is uncommon; however, de- 
spite its low incidence it presents frequent diagnostic 
problems due to the prevalence of cold thyroid nodules. 
Current common diagnostic modalities - clinical exami- 
nation, thyroid function tests, ultrasonography and thy- 
roid scintigraphy whether with 123I, 99mTc, 2°W1 or 
99mTc-sestamibi fa l to differentiate benign from malig- 
nant nodules and to provide a specific diagnosis. Fine- 
needle aspiration biopsy, although performed in a large 
number of patients, has significant limitations related to 
sampling errors in small turnouts. Furthermore, the 
small size of the collected samples makes it difficult to 
differentiate a follicular adenoma from a follicular carci- 
noma. Several authors have suggested a role for FDG 
PET in this differential diagnosis. Bloom et al. studied 
19 patients, 12 with solitary thyroid nodules and seven 
with multinodular goitres, using a multislice single area 
non-attenuation-corrected technique [271,272]. Four of 
the 12 nodules were malignant while the multinodular 
goitres were benign. They reported ifferent DURs (dose 
uptake ratio: a semiquantitative ndex of FDG uptake pa- 
rameter) between cancers (three papillary and one follic- 
ular) and benign nodules (eight follicular adenomas). 
One patient with a papillary cancer had another small fo- 
cus of papillary cancer within the same lobe that was not 
visualized. Also an incidental papillary cancer (1 ram) in 
a patient with a multinodular goitre (independent from 
the dominant nodule) was not visualized. The authors re- 
ported no overlap in DUR values between visualized be- 
nign and malignant lesions but the separation was nar- 
row. The uptake in cancer is quite variable and this dis- 
crimination is at variance with some other reports. For 
instance, Joensuu et al. [273] noted FDG accumulation 
in three patients with a Harthle cell carcinoma, an ana- 
plastic carcinoma nd a thyroid lymphoma but showed 
only slight or no retention in three papillary carcinomas. 
Three of eight histopathologically benign tumours also 
accumulated FDG. In addition, it must be mentioned that 
FDG uptake is not uncommonly seen in an otherwise 
normal thyroid for unidentifiable r asons. We therefore 
believe that the diagnostic application of FDG in pa- 
tients with undiagnosed solitary thyroid nodules is not 
currently warranted. 
Postoperative staging. Imaging of metastases of thyroid 
carcinoma with FDG was first performed by Joenssu and 
Ahonen [274]. They studied three patients with multiple 
metastases of thyroid carcinoma (one papillary and two 
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follicular) using a specially modified gamma camera (1- 
inch crystal and special collimator). Metastases that ac- 
cumulated only FDG, only iodine or both iodine and 
FDG could be demonstrated. Metabolic heterogeneity 
was seen between different metastases in all patients. 
FDG accumulation may also differ between different 
metastases of the same patient. The uptake of FDG in 
metastases was shown to increase in parallel with their 
progression. They concluded that metastases that accu- 
mulate FDG but net 13ii may behave more aggressively 
than metastases that accumulate 131I but not FDG. 
Metabolic heterogeneity was confirmed by Fridrich et 
al. [275], Scott etal. [276] and Feine et al. [277]. Frid- 
rich studied 12 patients with known thyroid carcinoma 
and suspected metastases prior to iodine therapy. FDG 
demonstrated 29 lesions, whereas diagnostic iodine scin- 
tigraphy (5 mCi 131I) revealed only ten. FDG demon- 
strated more lesions in nine patients. Post therapy iodine 
imaging (100 mCi 131I) confirmed positive uptake in 20 
lesions. Iodine scintigraphy is insufficient to exclude the 
presence of metastases that may respond to 131I therapy. 
A positive FDG finding without iodine uptake after 131I 
therapy should lead to another therapeutic strategy. 
In 24 patients with differentiated thyroid carcinoma, 
Feine etal. [277] reported an alternating ("flipflop") pat- 
tern of metastases with either 131I or FDG uptake. The 
FDG uptake showed an inverse proportionality o iodine 
uptake and to tumour differentiation. Grunwald et al. in- 
terpreted increased glucose metabolism as a sign of 
higher malignancy [278]. 
Sisson etal. [279] reported a patient with a pulmona- 
ry metastasis from papillary thyroid carcinoma. This tu- 
mour barely concentrated 131I but was well seen using 
FDG. FDG uptake was lower after T 4 therapy and reduc- 
tion in the TSH level. Sissons et al. suggested the use of 
FDG uptake measurement as a means to optimize T 4 
treatment level and TSH suppression in patients with 
thyroid metastases unlikely to respond to t3~I, external 
beam radiation or surgical resection. 
Preoperative staging. The annotated bibliography com- 
piled by the Western PET Association suggests preoper- 
ative staging as another potential role for PET in patients 
with thyroid cancer [280]. Indeed, it would be useful to 
document the presence of metastases prior to surgery for 
consideration of surgical resection rather than subse- 
quent radioiodine treatment. However, no published re- 
port addresses this issue. 
Parathyroid 
Conflicting reports are available on the role of FDG PET 
in localizing abnormal parathyroid tissue. Neumann et 
al. [281], using attenuation-corrected regional body PET, 
described correct localization of 17 of 18 parathyroid ad- 
enomas and two of four hyperplastic glands in 17 pa- 
tients. There were three false-positive findings including 
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two follicular adenomas. Sisson and others, however, 
have reported negative results [282]. They studied seven 
patients with documented parathyroid adenomas and one 
with a recurrent hyperplastic gland (weight 0.15-4.5 g). 
Even in retrospect no focus of FDG radioactivity could 
be found to represent the abnormal parathyroid gland, 
and this concurs with our experience. 
Adrenals 
There are few reports on adrenal imaging with PET. One 
report has concerned the detection of medullary phaeo- 
chromocytoma while another has evaluated the role of 
PET in differentiating indeterminate adrenal mass in pa- 
tients with cancer [121,283]. No report has as yet dealt 
with the diagnosis of hyperfunctioning cortical tumours. 
Phaeochromocytoma accumulates FDG and can be 
imaged by the PET method. Shulkin et al. have reported 
on two patients in whom metaiodobenzylguanidine 
failed to demonstrate he tumour [283, 284]. FDG PET 
enabled correct localization of the tumour in both cases 
with high contrast and should be useful in turnouts that 
do not accumulate MIBG. FDG also accumulates in neu- 
roblastoma [285]. 
Incidentally discovered adrenal masses are frequent. 
In patients with cancer, they have a 27%-36% probabili- 
ty of being malignant [286]. Currently, biopsy is re- 
quired for differential diagnosis despite potential com- 
plications, and displays an accuracy of 80%-100% 
[287]. Boland etal. [121] have evaluated the ability of 
PET to characterize adrenal masses in patients with can- 
cer. They reported on 24 adrenal masses in 20 patients. 
PET helped in the correct differentiation f benign from 
malignant adrenal lesions in all patients. The SUV val- 
ues ranged from 2.9 to 16.6 in the 14 malignant lesions 
and from 0.2 to 1.2 in the ten benign lesions. Although a 
larger sample size is required to confirm these observa- 
tions, FDG PET appears promising for the evaluation of 
incidentally identified adrenal masses in patients with 
cancer. 
Neuroendocrine tumours 
Endocrine pancreatic tumours can be visualized by PET. 
According to Ahlstr6m etal. [288], 11C-5-HTP displays 
higher uptake than does ~1C L-dopa in secreting tumours 
but these amino acid precusors appeared less useful than 
CT for the detection of non-functioning tumours. Little 
experience is available concerning the use of FDG in en- 
docrine pancreatic tumours. In our hands [289], FDG 
has appeared useful for the detection of carcinoid and 
neuroendocrine tumours as it demonstrated more lesions 
than indium-octreotide in six patients tudied. The FDG 
uptake varied markedly from patient o patient, however, 
possibly reflecting the metabolic activity of the tumour. 
In a subsequent patient with octreotide-demonstrated 
gastrinoma, FDG PET was completely normal. 
European Journal of Nuclear Medicine VoI. 23, No. 12, December 1996 
1660 
Pituitary tumours 
Pituitary adenomas have been more frequently studied 
with J tC-methionine orwith dopamine D2 receptor bind- 
ing ligand (for functioning prolactinomas). In the experi- 
ence of Murh et al. [290] and Bergstr6m et al. [291], all 
untreated pituitary adenomas studied emonstrated high 
FDG uptake, similar to or higher than normal brain tis- 
sue. The tumour to brain ratio was, however, higher for 
methionine. Also the variability of FDG uptake in non- 
secreting adenomas was higher than that of llC-L-me- 
thionine and the correlation with hormone secretion was 
less good. Dopamine agonist treatment seemed to reduce 
FDG uptake as well as methionine uptake. FDG uptake 
in meningioma was considerably ower than in pituitary 
adenomas and this feature could be used for differential 
diagnosis. Although most cases can be effectively diag- 
nosed using more conventional imaging, PET may have 
a role in selected instances. 
Musculoskeletal neoplasms 
Musculoskeletal tumours were among the first non-brain 
turnouts to be imaged by PET. Kern et al. [292] reported 
on four patients with soft tissue tumours and one with 
osteogenic sarcoma. As in the brain, a correlation be- 
tween the grade of the turnout and the extent of FDG up- 
take was noted in these patients. This observation was 
confirmed by Adler et al. [37] in five patients with lipo- 
sarcoma of the thigh. DUR averaged 1.38 in low-grade 
and 2.45 in high-grade tumours, suggesting a role of 
FDG in this metabolic distinction. Adler et al. [38] ex- 
tended this observation i 25 patients presenting six be- 
nign lesions and 19 malignant lesions of various grades. 
High-grade malignancies had DUR values >1.6 while le- 
sions with values <1.6 were either benign or low grade. 
In a recent study, Nieweg et al. [293] examined the cor- 
relation between tumour grade and FDG metabolic rate 
(regional glucose metabolic rate and SUV). They studied 
18 patients with soft tissue sarcomas and four with be- 
nign soft tissue lesions. All sarcomas were clearly visu- 
alized, as was one benign lesion. An equivocal scan was 
obtained in another benign lesion. A correlation was 
found between glucose metabolism and the histopatho- 
logical malignancy grade. Such a correlation was not 
demonstrated for the SUV (calculated as turnout aver- 
age). Benign lesions could be distinguished from high- 
grade malignant lesions but not consistently from lesions 
with low or intermediate malignancy grades. 
Preoperative diagnosis and staging. The clinical impact 
of PET imaging in soft tissue masses was explored by 
Griffeth et al. [294]. They performed limited axial field 
of view scanning in 19 patients with ten malignant and 
ten benign lesions. DUR values provided complete dis- 
crimination between benign and malignant lesions. Most 
patients undergo an extensive valuation before surgical 
diagnosis with the goals of evaluation of the nature of 
the primary lesion, assessment of local invasion and ex- 
tension, and detection of possible distant metastases. All 
questionable l sions must be presumed malignant before 
definitive surgery as there is reluctance to violate tissue 
planes for simple biopsy. Definitive diagnosis is fre- 
quently only made at complete or radical surgical resec- 
tion to avoid seeding or contamination f adjacent tissue 
planes with malignant cells. 
Current results support he use of PET to help in this 
preoperative diagnosis even though accuracy cannot be 
expected to be 100% and the method of quantification 
must be better standardized [78]. For those lesions 
shown to be malignant, PET may also aid in the preoper- 
ative planning of biopsy and therapy. Indeed, it provides 
information regarding the distribution of metabolically 
active tumour tissue relative to the abundant necrotic, 
oedematous, inflammatory or postoperative changes in 
otherwise normal surrounding tissue. PET appears more 
accurate that CT or MRI in the selection of sites with the 
greatest concentration f cellular neoplastic elements for 
histopathological analysis. In this indication PET may be 
particularly useful in patients with previous urgery, che- 
motherapy or radiation therapy that has resulted in ana- 
tomical changes and distortion of normal planes [295, 
296]. It can predict he benign nature of recurrent masses 
or allow a conservative biopsy and monitor approach 
rather than extensive surgical excision of suspicious but 
potentially benign tissues. 
PET also aids in the detection of regional or distant 
metastases [293]. In the latter study, 12 suspicious 
lymph nodes (1-2 cm in diameter) were confirmed as 
metastatic while four normal size involved lymph nodes 
were identified. Metastatic mediastinal lymph nodes and 
an unsuspected primary leiomyosarcoma of the oesopha- 
gus were also diagnosed. 
PET can be useful to detect he presence of residual 
or recurrent malignant disease after surgery. In osteogen- 
ic sarcoma, detection of pulmonary metastases can also 
be performed using lSF-fluorine ion to identify an extra- 
osseous ite of bone formation or calcification [297]. 
Finally, Nieweg et al. report on the role of FDG PET 
in evaluating the results of isolated limb perfusion thera- 
py in a patient with a locally advanced liposarcoma. Be- 
fore perfusion, a high glucose consumption of the tu- 
mour was demonstrated which was absent after perfu- 
sion of TNF-o~, interferon-gamma and melphalan. Sub- 
sequent excision confirmed complete necrosis of the tu- 
mour [295]. 
Ovarian carcinoma 
Ovarian carcinoma is the leading cause of death among 
gynaecological tumours [298]. It has spread throughout 
the pelvis in about wo-thirds of all patients at the time 
of diagnosis. Non-invasive staging is usually performed 
using the clinical examination, ultrasonography, urogra- 
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phy and tomodensitometry. The search for lung and 
pleural metastases a  well as for hepatic metastases is 
systematic. Confirmation of the disease and definition of 
its true extent is usually not complete until the time of 
initial surgery. Therapy after careful evaluation of the le- 
sion consists in maximum early resection followed by 
chemotherapy and/or adiotherapy. Post-therapy follow- 
up is facilitated by monitoring tumoral markers, espe- 
cially CA 125 (but also CEA and alpha-fetoprotein or ~- 
HCG in specific tumours, i.e. yolk sac tumours and cho- 
riocarcinoma); CA 125, however, is not elevated in all 
patients with residual or recurrent tumours. Mortality af- 
ter surgery and radio- or chemotherapy remains high. In- 
deed, even after negative second-look surgery, recurrenc- 
es occur in 40%-63% of cases [298]. These recurrences 
and the mortality primarily result from occult metastases 
involving the peritoneal surfaces of the pelvis and abdo- 
men and the retroperitoneal lymph nodes. Unfortunately, 
current diagnostic techniques, including CT or MRI and 
laparoscopy or culdocentesis, lack sensitivity and speci- 
ficity for accurate diagnosis and staging of primary and 
residual or recurrent disease. New methodologies are 
needed to optimize treatment planning in ovarian carci- 
noma [153] and FDG PET has been evaluated. 
Successful imaging of ovarian cancers with FDG was 
first reported by Wahl et al. [299]. The largest experi- 
ence has been reported by Hubner et al. [300]. These au- 
thors presented ata from an extended series at the ICP 
meeting [301]. Ninety patients presenting with ovarian 
masses were studied by limited field or whole-body PET 
and CT prior to laparotomy for suspected ovarian cancer. 
High sensitivity and specificity (89% and 92%) were re- 
ported, with high positive and negative predictive values 
(94% and 85%). PET identified occult foci of active tu- 
mour not apparent on morphological studies (CT sensi- 
tivity 72%, specificity 43%) (Table 8). Data in recurrent 
disease were available in 44 cases. Again, high sensitivi- 
ty and specificity were demonstrated (94% and 100%). 
Other groups have concentrated onpatients uspected 
of recurrent disease. Karlan et al. [302] performed 
whole-body studies in 12 patients prior to second-look 
surgery. PET-defined disease in six patients was con- 
firmed by surgery. Six patients with negative scans had 
no visible disease at surgery; however, in five of these 
patients microscopic disease was defined by pathology. 
Casey et al. [303] described 19 patients with suspected 
recurrent tumour after initial surgical resection (based on 
clinical signs or biology). The final diagnosis was estab- 
lished by surgery or clinical follow-up. FDG demon- 
strated 10 of 11 histologically proven tumours, and there 
was one false-positive r sult. Sensitivity was 91% and 
specificity 88%, versus 55% and 75% for CT and 73% 
and 100% for tumour markers. Two patients with meta- 
static liver lesions were also detected by PET. Results of 
Avril et al. [304], however, draw attention to the lack of 
specificity of FDG in patients with pelvic abcesses or in- 
flammatory foci. 
PET and FDG appear useful to guide surgery through 
a more complete staging of abdominal nd extra-abdom- 
inal tumours, and to avoid second-look surgery, e.g. in 
cases of extensive dissemination. 
Genito-urinary neoplasms 
Few reports have been devoted to the use of FDG PET in 
patients with genito-urinary neoplasms. The available re- 
ports, however, are rather encouraging. Imaging of kid- 
ney cancer using FDG has been reported by several 
groups [305, 306]. Prolonging the delay between injec- 
tion and imaging is frequently sufficient o allow ade- 
quate contrast for tumour imaging. Wahl et al. [306] 
have presented results of pilot animal and human stud- 
ies. They have demonstrated both adenocarcinomas and 
transitional cell carcinomas, but the place of PET in the 
diagnosis and staging of these tumours remains to be de- 
fined. 
Bladder cancer can also be demonstrated using FDG 
[307]. Visualization of the primary tumour is possible 
provided the urinary activity has a low concentration. 
Regional nodal disease can also be demonstrated [308], 
preferably using iterative reconstruction techniques. Ha- 
rney et al. [307] have reported successful detection of 
distant metastasis. 
PET also appears effective for the visualization of 
testicular carcinoma nd in particular germ cell carcino- 
ma [309]. In a study of 21 patients with stage II-IV tes- 
ticular germ cell turnouts, Wilson et al. [310] evaluated 
various clinical PET indications using a multiwire pro- 
portional PET system and FDG. Despite the limited sen- 
sitivity and resolution of such a system, they provided 
convincing arguments for its value in detecting metastat- 
ic disease (active disease >2 cm in diameter). In patients 
with malignant teratoma nd residual masses after che- 
motherapy, PET differentiates well-differentiated terato- 
ma, benign lesions and fibrosis from poorly differentiat- 
ed viable malignant tumours. Surgery of differentiated 
teratoma remains indicated, however, as relapse is not 
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infrequent (12%). Determination f the nature of residu- 
al masses might be more important in seminoma. Final- 
ly, PET and FDG appear useful to follow up the results 
of therapy. Confirmation i  a larger number of patients 
and using a more quantitative t chnique is needed. 
Results in prostate cancer have been less favourable 
[311]. Several preliminary reports suggest hat PET 
misses a significant number of primary tumours and 
nodal metastases [312]. Furthermore, data from Shreeve 
et al. [131] suggested that close to 50% of patients with 
metastatic prostate carcinoma do not have their bone le- 
sions visualized by FDG PET. 
Brain tumours 
Most PET studies performed for the evaluation of brain 
tumours concern gliomas, the most frequent ype of 
primitive brain tumours. According to the W.H.O. classi- 
fication, gliomas include four malignancy grades corre- 
sponding to different therapeutic indications and progno- 
sis. 
Differential diagnosis. When lesions are demonstrated 
by CT or MRI with contrast enhancement and peripheral 
oedema, differential diagnosis usually has to be made 
between a tumour and an abscess: PET shows high FDG 
uptake in tumoral lesions (especially high-grade l sions) 
[11, 33,314], and no or low uptake of FDG in abscesses; 
however, in some cases, tumours, even high-grade glio- 
mas, may exhibit low FDG uptake, whereas ome ab- 
scesses may exhibit high uptake of FDG [315] or 11C- 
methionine (MET) [316]. In patients with AIDS, FDG 
PET has proved useful to differentiate between brain 
lymphoma nd non-malignant lesions such as toxoplas- 
mosis or syphilis [317]. 
Dethy et al. studied the use of PET with FDG or 
MET in patients with chronic brain haematomas [318], 
and observed moderate uptake of both tracers in examin- 
ations performed 20-32 days after the initial symptoms. 
PET was not helpful at that time in differentiating be- 
tween neoplastic and non-neoplastic origins of an intra- 
cerebral haematoma. However, the uptake of both tracers 
decreased 76-103 days after the initial symptoms, and 
PET might hen be useful in detecting a tumour underly- 
ing the haematoma. 
When CT or MRI shows a non-enhancing lesion, the 
differential diagnosis must usually be made between a
low-grade glioma and a non-tumoral lesion such as glio- 
sis, post-traumatic s ar tissue, or even sometimes an 
ischaemic lesion. While in some cases of low-grade glio- 
mas PET may show increased FDG uptake, in most 
cases FDG uptake is decreased [11, 33, 314], as in non- 
tumoral lesions. In these cases, MET is very helpful, as 
the uptake of MET is increased in nearly all low-grade 
gliomas as well as in high-grade gliomas [319-323]. 
PET is, however, unsuccessful in differentiating between 
the various histological types of brain tumours, as high 
uptake of FDG is seen not only in gliomas but also in 
lymphomas [317, 324, 325], meningiomas [326], pituita- 
ry adenomas [327] and metastases [328]. 
In difficult cases, PET, performed in stereotactic con- 
ditions if necessary, can help to select the best site to 
perform a biopsy [329-334]. Levivier et al. [331] 
showed that the number of non-diagnostic rajectories of 
stereotactic biopsies was smaller if the target was de- 
fined by PET and CT rather than by CT alone. In low- 
grade lesions, where FDG uptake is usually low, MET or 
11C-tyrosine may be useful in detecting the best site for 
biopsy. 
Preoperative staging. Primitive brain tumours are usual- 
ly unifocal and do not metastasize. Staging therefore 
mainly concerns prediction of the grade of malignancy, 
delineation of the tumour, and determination f turnout 
heterogeneity. 
Since the initial description of the use of FDG PET in 
cerebral gliomas by Di Chiro et al. [33], a lot of studies 
have been performed, and have drawn the same conclu- 
sions: There is a clear correlation between the uptake of 
FDG and the histological grade of gliomas, and also be- 
tween the uptake of FDG and the survival prognosis [ 11, 
314, 335-337]. The usual visual pattern is a hot spot in 
high-grade lesions, and a cold spot in low-grade glio- 
mas; however, a cold spot may be seen in some high- 
grade gliomas; on the other hand, the presence of a hot 
spot in a low-grade glioma is usually an indicator of ma- 
lignant degeneration [338]. The same correlations are 
found when the ratio between tumour and the normal 
contralateral cortex (T/CTX ratio) is considered. Patron- 
as et al. [339] postulated that within high-grade gliomas, 
the uptake of FDG might be a more important prognos- 
tic factor than the histological grade, but most of the 
cases included in this study were already recurrences. 
The absolute values of glucose consumption are also 
correlated with the histological grade of gliomas, but 
there is some overlap between the grades, and most au- 
thors consider that, for clinical use, these calculations do 
not yield more information than visual analysis com- 
bined with a semi-quantitative evaluation of the T/CTX 
ratio. Moreover, the principle of quantitative glucose 
consumption calculation is cdntroversial in brain tu- 
mours [11, 340-342], and results can be modified by 
some medications such as corticosteroids [343] or barbi- 
turates [344]. Patients usually fast for 4-6 h before the 
PET examination, but Ishizu et al. [345] have calculated 
that glucose loading decreases FDG uptake in the nor- 
mal cortex more than in the turnout, resulting in an in- 
creased T/CTX ratio by 26%. In a study concerning 
grade II and III gliomas, Herholtz et al. [346] found a 
clear correlation between the uptake of FDG and the tu- 
mour cell density evaluated by multiple stereotactic bi- 
opsies. 
One exception to the correlation between FDG uptake 
and malignancy is the juvenile pilocytic astrocytoma,  
very benign lesion. Fulham et al. [347] found a high up- 
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take of FDG in these lesions, higher than in other low- 
grade astrocytomas nd equivalent to that in anaplastic 
astrocytomas. It is also known that these lesions usually 
exhibit contrast enhancement on CT or MR/. These 
"pseudo-malignant" features of a typically benign lesion 
are interpreted to reflect he unusual vascularity of pilo- 
cytic astrocytomas, while the increased glucose utiliza- 
tion rate might be related to expression of the glucose 
transporter. 
FDG PET can also show remote metabolic effects 
based on deafferentation by the lesion. A depressed cere- 
bellar glucose metabolism (cerebellar diaschisis) contra- 
lateral to brain tumours (or other lesions) usually occurs 
when they invade the motor cortex or the thalamus 
[348]. 
Methionine studies in brain gliomas have also shown 
a correlation between the uptake of this tracer and the 
histological grade, but to our knowledge no correlation 
has been reported between the uptake of MET and prog- 
nosis [320, 322, 349-352]. Few studies have compared 
FDG and MET; they have demonstrated that FDG is 
probably better for establishing the degree of malignan- 
cy, whereas MET better delineates the lesions, especially 
low-grade gliomas [319, 321,323,353,354]. 
In meningiomas, Di Chiro et al. [326] found a corre- 
lation between the tumoral glucose utilization, the ma- 
lignancy and the probability of recurrence. There was 
also a significant inverse correlation between the glucose 
metabolic rate and the doubling time. The strong corre- 
lation between FDG uptake and the clinical outcome led 
Di Chiro et al. to conclude that the metabolic rate is at 
least as important as the histological classification in 
these tumours. Borbely et al. [355] performed FDG PET 
in five patients with cranial or spinal neuromas, and 
found a higher uptake of FDG in the case where the tu- 
mour recurred than in the other cases where the lesion 
was stable over time. 
Postoperative valuation of residual' tumour. CT and 
MRI cannot reliably differentiate he presence of residu- 
al tumour from postoperative enhancement. Glantz et al. 
[356] have studied tumour patients after surgery, com- 
pared them with patients operated on for epilepsy, and 
compared gliomas before and after corticosteroid thera- 
py: they found that FDG uptake is not increased in the 
postoperative p riod (in epilepsy surgery or total tumour 
resection), is not affected by corticosteroid therapy, and 
accurately predicts the persistence of tumoral tissue, and 
thus early recurrence. 
Follow-up of therapy. In rats, Ito et al. [357] showed a 
15% decrease in glucose uptake by the normal brain 4 
days to 4 weeks after radiotherapy. In experimental rat 
brain tumours, the uptake of FDG [358] and MET [359] 
by the tumour decreased early after irradiation, except in 
radioresistant tumours. 
In humans, Mineura et al. [360] reported a paediatric 
case where a 50% decrease of FDG uptake after irradia- 
1663 
tion was highly consistent with the period of clinical re- 
lief. After a combination of radio- and chemotherapy, 
Ogawa et al. [361] measured a mean reduction of glu- 
cose consumption of 41% in tumours, and of 14% in 
normal brain tissue. Rozental et al. found that the tu- 
mour to white matter ratio increased 20%-100% 24 h af- 
ter chemotherapy [362], and then decreased to between 
22% above and 35% below baseline 28 days later. 
HNzer et al. [363] found no differences between FDG 
PET before and 6 and 12 months after radiochemothera- 
py in 15 glioblastomas. However, to our knowledge, no 
correlation has been demonstrated between prognosis 
and an early PET modification after treatment. 
In posterior fossa tumours and primitive neuroecto- 
dermal tumours, Holthoff et al. [364] found a good cor- 
relation between the modifications of FDG uptake be- 
fore and after treatment and the neuroradiological find- 
ings. FDG PET also corresponded to the duration of ini- 
tial clinical improvement. 
Differential diagnosis between tumour recurrence and 
radiation necrosis. It is most often impossible to make 
this differential diagnosis by CT or MR/in those patients 
who have been operated on and then treated by radiother- 
apy, and present a few months later with a partially ne- 
crotic lesion and peripheral contrast enhancement. FDG 
PET proved useful in these cases to differentiate umour 
recurrences exhibiting a high uptake of FDG from radia- 
tion necrosis in which the uptake of FDG is low [356, 
365-367]. In this indication, FDG PET proved superior to 
rubidium-82 PET [367]. Some false-negative FDG cases 
have been demonstrated, however, especially in recurrenc- 
es of low-grade gliomas but also in histologically proven 
recurrences of high-grade gliomas. Some false-positive 
cases have also been demonstrated [361,368-371]. False- 
negative cases may especially correspond to small esions 
included in the cortex, or to partially cystic or necrotic le- 
sions. The usefulness of FDG PET in the differential diag- 
nosis between recurrence and radiation ecrosis has also 
been demonstrated after interstitial brachytherapy or ra- 
diosurgery for metastases [368, 372]. 
In recurrences of proven high-grade gliomas, Patron- 
as et al. [339] identified all the tumours, and demonstrat- 
ed a correlation between the FDG uptake (ratio of the tu- 
mour to the corresponding contralateral brain) and the 
median survival time: 19 months if the ratio was equal to 
or less than 1.4, compared to 5 months if the ratio was 
greater than 1.4. They also suggested that FDG PET in 
these cases could be a more important prognostic factor 
than histology, as the survival of patients with grade IV 
gliomas with a low FDG uptake was better than that of 
patients with grade II1 gliomas with a high FDG uptake. 
These conclusions were later confirmed by Alavi et al. 
[93], who observed a median survival of 7 months for 
the hypermetabolic tumours, compared to 33 months for 
the hypometabolic esions. 
In a few studies performed with MET, this tracer also 
proved useful in detecting biologically active residual or 
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recurrent brain tumours, and could yield less false-nega- 
tive results than FDG PET [369, 373,374]. In our expe- 
rience, MET proved much better than FDG in delineat- 
ing tumour recurrences, and usually clearly depicted 
low-grade lesions and some high-grade lesions that were 
not seen with FDG [354], 
How to improve clinical PET 
The use of 3D-imaging techniques and of large field of 
view detectors has considerably increased system sensi- 
tivity and reduced statistical noise, thereby improving 
clinical PET. 
Reduction in image artefacts can be obtained through 
transmission correction, iterative reconstruction and bet- 
ter patient preparation. Attenuation correction, up to 
now impractical for whole-body imaging (due to the ex- 
cessive duration of transmission acquisition), will be- 
come possible with the use of a single-photon emitter 
(137Cs). Furthermore, the use of transmission image seg- 
mentation has been shown to decrease statistical noise 
and improve the quality of image reconstruction. Maxi- 
mum likelihood iterative reconstruction also decreases 
artefacts, especially in areas of high heterogeneous count 
activity, and can facilitate image interpretation. Im- 
proved speed of computing and better algorithms make 
these easier to use in clinical practice. Finally, better pa- 
tient preparation, adequate fasting, glucose level verifi- 
cation, adequate relaxation or use of diazepam as a mus- 
cle relaxant and use of forced diuresis for pelvic exami- 
nation (furosemide) can also contribute to the quality of 
the examination. 
Interpretation can also be improved by anatomical 
correlation, in particular through the use of image fusion 
with structural images. Accurate quantification could 
also significantly contribute to interpretation. Most im- 
portant, however, is patient selection. As FDG is a non- 
specific tracer, its accuracy depends on proper patient 
selection. Inclusion of patients with low disease proba- 
bility increases the likelihood of false-positives, and the 
technique is not suited to unselected screening. Howev- 
er, in adequately selected groups with proper diagnosis 
verification, the technique has been shown to have a 
considerable impact. 
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